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Abstract 
Dietary biomarkers are objective measures of food or nutrient intake and can be 
related to endpoints in epidemiological studies, used in the validation of dietary 
assessment instruments and used to check of compliance during intervention studies. 
Alkylresorcinols (AR), phenolic lipids present exclusively in the outer parts of 
wheat and rye grains, have been suggested as biomarkers of whole grain wheat and 
rye intake.  
The overall aim with this thesis was to evaluate AR as specific biomarkers of 
whole grain wheat and rye intake. This was conducted by developing a rapid GC-
MS method for the analysis of AR in plasma and by studying AR pharmacokinetics, 
dose-response, reproducibility and relative validity in human intervention studies 
under controlled intake conditions. Factors affecting plasma AR concentrations 
were investigated in free-living Danish women.  
The method developed proved suitable for the analysis of relatively small sample 
volumes (50- 200μL). The results showed that AR in fasting plasma samples can be 
used as short-term concentration biomarkers, reflecting the intake range normally 
found in the Nordic countries in a dose-dependent manner. One or two repeated 
measurements of AR were found to adequately describe a subject’s average plasma 
AR concentration at regular and constant intake. In free-living Danish women, rye 
bread was identified as the major factor affecting plasma AR concentration and 
there was no evidence of non-dietary factors or other foods having an effect. In 
conclusion, our results support that AR can be used as biomarkers in intervention 
studies on whole grain wheat and rye and probably also in epidemiological 
endpoint- and validation studies.  
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1 Background 
1.1 Whole grain and human health 
Cereals have been an important part of the human diet since the advent of 
agriculture about 10 000 years ago and during the majority of that time they 
have been consumed as whole grain (Spiller, 2002). It is only within the last 
hundred years that most people have consumed refined grains (Slavin, 
2005a). The positive health effects of whole grain were recognised early and 
during the past two hundred years physicians and scientists have 
recommended whole grain to prevent constipation. In the early 1970s, the 
‘fibre hypothesis’ was proposed by Burkitt and colleagues (Burkitt et al., 
1974). It was suggested that non-refined foods, such as whole grains, fruits 
and vegetables, which provide dietary fibre along with other constituents, 
have a protective effect against ‘Western’ diseases such as coronary heart 
disease and colon cancer. Today, there is a general long-standing view 
among major governmental, scientific and non-profit organisations, mainly 
based on epidemiological findings, that the Western population would 
benefit from increased consumption of whole grain foods as a way of 
reducing the risk of developing chronic diseases (Cleveland et al., 2000; 
Marquart et al., 2005; National Food Institute, 2008). As a result, whole 
grain intake, as a part of a healthy diet, has been directly (USA) or indirectly 
(Nordic countries and UK) promoted  in the dietary guidelines in a number 
of countries and by WHO (Becker et al., 2004; Food Standards Agency, 
2008; U.S Department of Health and Human Services & U.S. Department 
of Agriculture, 2005; World Health Organization, 2003). 
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The cereal grain is the fruit, called caryopsis, of plants belonging to the grass 
family (Poaceae or Gramineae) (Hoseney, 1994). Whole grain refers to ‘intact, 
ground, cracked or flaked caryopsis, whose principal anatomical 
components- the starchy endosperm, germ and bran (Figure 1)- are present 
in the same relative proportions as they exist in the intact caryopsis’ 
(definition by AACC, 1999). This definition is also used by U.S. Food and 
Drug Administration (FDA)(2006). Cereals typically included in whole grain 
foods in the Western world are wheat, oats, rye, rice, barley and corn but 
also sorghum, and millet may be included as well as buckwheat, amaranth 
and wild rice, although not all of them are true cereals in the botanic sense 
(Cleveland et al., 2000; Jacobs & Steffen, 2003; Slavin, 2005b; Swedish 
Nutrition Foundation, 2004; Thane et al., 2007). There is currently no 
general, world-wide accepted definition of whole grain products, but 
typically they contain a certain proportion of intact, flaked or broken 
kernels, coarsely ground kernels or flour of whole grain. Different 
definitions have been used across studies, both in respect to the cereals that 
are included and to the proportion of whole grain in the food. Many of the 
studies on whole grain and disease have used the definition by Jacobs et al. 
(1998) which is a broad definition, but other more strict definitions have 
been used as well (Table 1). 
 
 
Figure 1. A principle sketch of a wheat caryopsis modified from Marquart et al. (2005).   11 
 
Table 1. Selected definitions of whole grain product definitions 
Reference Cereals  included  Constituents 
included 
Proportion of 
product weight (%) 
U.S. Food and Drug 
Administration 
(FDA) (2006) 
 
Armanth, barley, 
buckwheat, corn, 
millet, rice, rye, oats, 
sorghum, triticale, 
wheat and wild rice 
According to AACC 
definition (see text ) 
 51% whole grain 
ingredients by 
weight/reference 
amount customarily 
consumed (RACC) 
per day 
Swedish Nutrition 
Foundation (2004) 
Wheat, oats, barley 
and rye 
Intact or ground 
whole grain seed 
kernels (i.e. cereal 
grains where all 
components 
contained in the 
grain seed, along 
with the seed shell, 
are included) 
Flour, grains and 
flakes must be 100% 
whole grain and the 
whole grain 
ingredient must 
exceed  50% weight 
of product dry 
matter 
Thane et al. (2007)  Wheat, oats, rice, 
rye, barley, and corn 
(popcorn)  
According to AACC 
definition (see text) 
  10%  
Jacobs et al. (1998)  Wheat, rye, oats, 
barley and rice 
Dark bread, brown 
rice, popcorn, wheat 
germ, cooked 
oatmeal, bulgur, 
couscous, breakfast 
cereals, bran   
  25% whole grain  
Jensen et al. (2004)  Wheat, oats, rice, 
barley, rye, 
buckwheat, corn 
(popcorn), amaranth, 
psyllium 
According to AACC 
definition (see text ) 
Amount whole grain 
in product (g) was 
counted 
National Food 
Institute (2008) 
Barley, corn, wheat, 
rye, oats, sorghum, 
millet and rice 
According to 
definition similar to 
AACC (see text) 
 51% whole grain 
on product dry 
weight basis 
Whole grain is a rich source of dietary fibre and a number of bioactive 
components, including minerals, vitamins, tocols, phytosterols, lignans and 
cinnamic acids. Together, these are sometimes referred to as the dietary fibre 
complex, which has been suggested to account for the positive health effects 
(Jacobs et al., 1995; Jacobs & Steffen, 2003; Jensen et al., 2006; Slavin et al., 
1997). 
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Many of the bioactive compounds are localised in the bran and germ which 
together corresponds to approximately 20% of the total kernel weight 
(Jacobs & Steffen, 2003). Evidence of the health benefits is mainly derived 
from epidemiological studies which is showing the associations and not 
necessarily the causal link between whole grain intake and health 
(Potischman & Weed, 1999). The underlying mechanisms for the protective 
effects are to a large extent unknown and the results from epidemiological 
studies still remain to be confirmed by randomised clinical trials (RCTs) 
(Andersson et al., 2007; Kelly et al., 2007; Priebe et al., 2008). 
1.1.1 Epidemiological evidence for health benefits of whole grain 
A number of epidemiological studies have been reported where whole grain 
intake has been related to a relatively consistent inverse risk of several 
chronic diseases such as cardiovascular diseases (including coronary heart 
disease (CHD), ischeamic heart disease (IHD) and ischaemic stroke) and   
type 2 diabetes (Kelly et al., 2007; Mellen et al., 2006; Priebe et al., 2008).  
A meta-analysis based on seven cohort studies showed a 21 % risk reduction 
for CHD when comparing 2.5 whole grain servings/d with 0.2 servings/d 
(OR: 0.79, [95%-CI 0.73-0.85]) (Mellen et al., 2006). Many of the studies 
were conducted in the USA, where the whole grain intake is low 
(Cleveland et al., 2000) and mainly consists of wheat (65-75%) (Slavin, 
2005a), but some were conducted in the Nordic countries, where the whole 
grain intake is higher (Montonen et al., 2003). However, the protective 
effect reported has been of the same magnitude, suggesting that whole grains 
of different species have similar effects and that even a small intake of whole 
grain is associated with the desirable protective effect (Jacobs & Steffen, 
2003; Jensen et al., 2004; Koh-Banerjee et al., 2004). Whole grain intake 
and cereal fibre have been consistently linked to a decreased risk of 
developing type 2 diabetes, with 10 out of 11 prospective cohort studies 
showing a significantly reduced risk in a recent Cochrane review (Priebe et 
al., 2008). High whole grain intake and cereal fibre intake were associated 
with a 27-30% and 28-37% decreased risk of developing diabetes type 2, 
respectively. Whole grain intake has also been associated with a significantly 
lower BMI in most observational studies (Harland & Garton, 2007), but it is 
not clear whether this effect is independent of cereal fibre and a healthy life-
style (National Food Institute, 2008). Several studies in different cohorts 
have investigated the relationship between whole grain intake and different 
cancer diseases and the results have been pointed in different directions 
(Larsson et al., 2005; Lucenteforte et al., 2008; McCullough et al., 2001; 
Schatzkin et al., 2007).     13 
1.1.2 Intervention studies  
Only a limited number of intervention studies on whole-grain and disease 
have been published. Most of these studies have been short-term studies on 
risk markers or intermediate endpoints of CVD and diabetes. A Cochrane 
analysis of 10 small RCTs (most of them studying oats) showed a small but 
significant reduction in serum total cholesterol and LDL cholesterol (-0.20 
mmol/L [95% CI -0.31;  -0.10] and -0.18 mmol/L [95% CI -0.28; -0.09], 
respectively) and in risk factors for CVD and type 2 diabetes (Kelly et al., 
2007). Preliminary results from two large non-blinded RCTs conducted in 
the UK show no effect of whole grain intake on CVD risk markers. In the 
‘WholeHeart study’, 300 non-whole grain consumers were assigned to 
either 16 weeks with 3 portions/d or 8 weeks with 3 portions/d + 8 weeks 
with 6 portions/d. The primary response variable was LDL cholesterol, 
where no effect was observed (Professor Chris Seal, pers. Comm. 2008). In 
another study, 221 subjects were randomly allocated to three groups, where 
they were advised to consume 3 portions/d of refined grain, whole grain 
wheat or whole grain wheat plus whole grain oats for 12 weeks. Preliminary 
results showed no effect on blood biomarkers, but a significant reduction in 
systolic and diastolic blood pressure in the two whole grain groups 
compared with the refined grain group (Dr Frank Thies, pers. Comm. 
2008). No RCTs have been published where whole grain intake has been 
related to type 2 diabetes endpoints (Priebe et al., 2008).  However, small, 
short-term intervention studies have evaluated the effect of whole grain 
intake on insulin sensitivity, which is related to type 2 diabetes (Andersson et 
al., 2007; Pereira et al., 2002). The results have been conflicting, and there is 
a need for long-term RCTs, using suitable intermediate endpoints, to 
establish whether whole grain intake protects against type 2 diabetes (Priebe 
et al., 2008). No long-term RCTs have been reported where the effect of 
whole grain products on body weight have been investigated (National 
Food Institute, 2008).   14 
1.2 Whole grain intake estimation methods and their limitations 
In epidemiological studies, there is a desire for cheap but accurate methods 
for estimation of habitual dietary intake during the etiologically relevant 
time period (usually a time period of years) (White et al., 1998). The 
assessment is often carried out using traditional dietary assessment methods 
such as food frequency questionnaires (FFQs), diet histories, 24-h recalls, 
and sometimes weighed food records (Willett, 1998). Those methods are 
either prospective or retrospective. The prospective methods often involve 
checklists or repeated recordings on different days. The retrospective 
methods are usually based on one or repeated 24-h recalls, diet history 
reports or FFQs. Diet histories and FFQs are designed to provide data on 
average intake over longer time periods, by asking about the usual frequency 
of food consumption (Willett, 1998). Traditional dietary assessment methods 
generally suffer from different types of errors (due to memory, motivation, 
etc.), which may affect their ability to accurately capture intake (Fraser, 
2003). Some of these errors can be accounted for by calibration against 
‘reference’ methods such as repeated weighed food records (Willett & 
Lenart, 1998). However, the assumption underlying such comparisons, that 
the errors in the two methods are not correlated, have been questioned in 
recent years, and biomarkers may instead be useful as reference methods 
(Subar et al., 2003).  
 
Apart from the general problems associated with the above-mentioned 
dietary assessment methods there are a number of obstacles to accurate 
assessment of whole grain intake that may affect evaluation of the health 
effects. Many of the studies have estimated whole grain intake as number of 
servings and have used different definitions of whole grain to calculate the 
number of daily whole grain servings (Jansen et al., 2004; Lang et al., 2003). 
The use of different definitions gives a large quantitative variation in actual 
whole grain content in a serving, but also a qualitative difference in the 
composition of nutrients and bioactive compounds, which might have 
implications for evaluation of the role of whole grain in the aetiology of 
chronic disease, since different components have different levels of activity. 
Thane et al. (2007) reported a 18-27% difference in whole grain intake by 
using the FDA definition compared with the less strict definition by Jacobs 
et al. (1998)(Table 1). In addition no uniform definition of serving size has 
been used across studies (Lang & Jebb, 2003) and different cereals have been 
included in different definitions (Table 1).    15 
Different definitions may potentially lead to misclassification, which is likely 
to attenuate the effect of whole grain disease associations (Koh-Banerjee et 
al., 2004). To get a more precise estimate of whole grain intake, the g/d 
content has been calculated in several recent studies (Jensen et al., 2004; 
Koh-Banerjee et al., 2004; National Food Institute, 2008; Thane et al., 2005; 
2007). In two studies, a cut-off limit of  10% whole grain content of 
product fresh weight was still used (Thane et al., 2005; 2007). For accurate 
determination of g/d intake of whole grain, databases reflecting products 
used in the studied population are needed in order to avoid biased estimates. 
Large variation in whole grain content in different products used to build a 
certain product category may obscure the precision in estimated whole grain 
intake (Fraser, 2003). This can to some degree be overcome by using ‘open-
end’ questions where subjects can report the brand of product used (Jensen 
et al., 2004). 
 
Irrespective of whether whole grain intake is estimated as number of 
servings per day, calculated on products passing certain cut-off levels, or 
estimated as g/d based on a strict whole grain definition, measurement errors 
are likely, due to difficulties for consumers in distinguishing whole grain 
products among other products (Kantor et al., 2001). In addition, dietary 
assessment methods are very often not designed to assess whole grain intake 
and usually contain only a limited number of questions which can be used to 
rank subjects according to their whole grain intake. As a consequence, 
misclassification is likely.   
 
A biomarker of intake could thus be used to overcome some of the obstacles 
related to traditional dietary assessment methods, and hence replace estimates 
of intake derived from those, or be used for studying the measurement 
errors in the traditional dietary assessment methods, i.e. b e  u s e d  f o r  
validation purposes (Beaton et al., 1997; Bingham, 2002). A few biomarkers 
of whole grain intake have been suggested and are discussed in the following 
sections. 
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1.3  Dietary biomarkers 
1.3.1 Concepts and definitions 
Biological markers or biomarkers have been defined in different ways 
(Figure 2). Biomarkers can provide a link between diet and health and have 
the potential to aid the understanding of this connection by reflecting the 
exposure and/or the disease or health effect (Branca et al., 2001). However, 
a biomarker is not a diagnostic test, but rather an indication of an early 
change that is related to disease risk or health outcome (Grandjean, 1995).  
 
Figure 2. Selected definitions of biomarkers. 
Biomarkers can be broadly classified into three different types, those of 
exposure, effect and susceptibility (Figure 3) (Branca et al., 2001; Committee on 
Biological Markers of the National Research Council, 1987; Grandjean, 
1995). In the discussion of biomarkers in the reminder of this thesis, the 
concept of biomarkers is restricted to dealing with those reflecting dietary 
exposure. 
 
 
 
 
BIOMARKER DEFINITIONS 
“Cellular, biochemical, or molecular alterations measurable in biological media 
such as human tissues, cells or fluids” 
(Hulka, 1990) 
 
“A characteristic that can be objectively measured and evaluated as an indicator of 
normal biological processes, pathological processes or pharmacologic responses to 
therapeutic interventions” 
(Biomarkers Definitions Working Group, 2001) 
 
“Any substance, structure or process that can be measured in the body or its 
products and can influence or predict the incidence of outcome of disese”  
(International  Programme on Chemical Safety, 2001)   17 
  Biomarker of exposure Biomarker of effect
Exposure  Internal dose 
Biologically 
effective 
dose 
Early 
biological 
effect 
Altered 
structure/ 
function 
Clinical disease 
Biomarker of suceptibility
Figure 3. Biomarkers of exposure, effect and susceptibility and their relationships to events 
along the exposure-clinical disease axis. Adapted from  Bearer (2001). 
Exposure  
A biomarker of exposure may be an exogenous compound or a metabolite 
of such a compound that is related to exposure. Such a marker may be used 
to reflect dietary exposure and hence provide a link between dietary 
exposure and disease, especially in situations where traditional dietary 
assessment methods for different reasons provide poor intake estimates 
(Bingham, 2002; Hunter, 1998; Kaaks et al., 1997; Verhagen et al., 2004).   
Effect 
A biomarker of effect may be an indicator of an endogenous component of 
the biological system, a measure of the functional capacity of the system, or 
an altered state of the system reflecting the disease or health endpoint 
(Branca et al., 2001; Committee on Biological Markers of the National 
Research Council, 1987). In such a situation the biomarker could be a 
surrogate endpoint or outcome measure that is a laboratory substitute for a 
clinically meaningful result with a direct link to the causal pathway linking 
disease to outcome (Fox & Growdon, 2004) .   
Susceptibility 
A biomarker of susceptibility is an indicator of the susceptibility of a 
biological system to the challenge of exposure to a xenobiotic compound 
(Committee on Biological Markers of the National Research Council, 
1987). Genetic alterations such as mutations, gene amplifications or 
recombination in genes directly or indirectly involved in the initiation or 
progression of disease can be such biomarkers (Branca et al., 2001).  
   18 
1.3.2 The use of dietary biomarkers 
There are a great number of compounds that have been suggested and used 
as biomarkers of food and/or nutrient intake (some examples given in 
Tables 2 and 3). Biomarkers of dietary intake may serve different purposes in 
different types of studies. They may be used for validation of traditional 
dietary assessment instruments, as surrogate measures of intake or as being 
integrated measures of nutritional status for a nutrient (Potischman & 
Freudenheim, 2003). The requirements differ depending on the purpose. In 
intervention studies, biomarkers might be used as qualitative or quantitative 
measures of compliance. For example, fatty acid profiles in serum or adipose 
tissue can be used as indicators of short-term or long-term compliance to 
diets rich in certain fatty acids (Wolk et al., 1998). The excretion of para-
amino benzoic acid in 24-h urine collections can be used as a quantitative 
measure of the completeness of urine collection (Bingham & Cummings, 
1986). In prospective cohort studies, biomarkers could be useful as 
independent measures of intakes in the study of association between diet and 
disease risk, or as independent tools to confirm such associations derived 
using traditional dietary instruments (Kaaks et al., 1997). A biomarker might 
provide a more accurate estimate, or provide a more accurate ranking of 
intake than estimates derived from traditional dietary assessment methods, 
especially in situations where accurate food composition data are lacking 
(Kaaks et al., 1997).  
 
The objectiveness is a key feature of the biomarker, since it is independent of 
subjects’ recognition capacity, memory and motivation (Marshall, 2003). 
This feature has made some biomarkers useful for validation of other dietary 
assessment methods (Bingham, 2003; Kaaks et al., 1997; Kaaks, 1997; 
Livingstone & Black, 2003). This is because random errors in the biomarker 
(any variation that is uncorrelated to the individuals’ ‘true’ habitual intake) 
can be assumed to be statistically independent of subjects’ response in 
traditional dietary assessment (Kaaks et al., 1997). Many biomarkers of 
food/nutrient exposure have not been thoroughly evaluated and are not 
fully accepted by the scientific community (Verhagen et al., 2004).  
 
A thorough understanding of the nature of the biomarker is necessary, and it 
will to a large extent determines its use (Marshall, 2003). As discussed in 
section 1.3.4, dietary biomarkers can be sorted into different classes 
depending on whether they provide an intake correlate or a direct 
quantitative measure of intake (Kaaks et al., 2002; Tasevska et al., 2005).  
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1.3.3 Dietary biomarkers of whole grain intake 
There is currently no generally accepted biomarker of whole grain intake. 
The mammalian lignan enterolactone (ENL) has been evaluated as one such 
biomarker (Stumpf, 2004). ENL and enterodiol (END) are mammalian 
lignans formed from plant lignans by the microflora in the large intestine 
(Adlercreutz, 2007; Setchell et al., 1980). Whole grain, especially from rye, 
is rich in precursors of ENL and the concentration of ENL in plasma, serum 
and urine increases with whole grain intake (Jacobs et al., 2002; Juntunen et 
al., 2000; Kilkkinen et al., 2001). However, since there are several other 
sources of ENL precursors in the diet and since the formation of ENL is 
dependent on the gut microflora as well as other non-dietary determinants, 
ENL may rather reflect plant intake or a healthy life style in general (Johnsen 
et al., 2004; Kilkkinen et al., 2001; Linko-Parvinen et al., 2007; Sonestedt et 
al., 2007). At the international symposium “Whole Grain and Human 
Health” in Helsinki, Finland, in 2001, the group led by Professor Per Åman 
(Uppsala, Sweden) suggested that AR could be used as a biomarker of 
whole grain wheat and rye, due to their almost unique presence in the outer 
parts of these cereals (Ross et al., 2001b). A method for the analysis of AR in 
plasma was developed and initial biomarker evaluation studies were 
conducted by a Finnish research group led by Professor Herman Adlercreutz 
(Linko-Parvinen, 2006; Linko-Parvinen et al., 2007; Linko et al., 2005; 
Linko & Adlercreutz, 2005; Linko et al., 2002).   22 
 
1.3.4 Classification of dietary biomarkers 
 
Recovery biomarkers 
Recovery biomarkers quantitatively reflect the balance between intake and 
output (Bingham, 2002; Kaaks et al., 1997; Livingstone & Black, 2003; 
Tasveska et al., 2008). There are currently only a few biomarkers that can be 
allocated to this category. Examples of such biomarkers are 24-h urinary 
nitrogen excretion as a marker of protein intake (Bingham, 2003), doubly 
labelled water for energy intake (Livingstone & Black, 2003) and 24-h 
urinary potassium excretion for potassium intake (Tasevska et al., 2006). 
Recovery biomarkers have a particular role for validation of other dietary 
methods, since they can be quantitatively measured and compared with 
traditional dietary assessment methods on the same scale (Kaaks et al., 1997).    
 
Concentration biomarkers 
A concentration biomarker is a measure of a nutrient or a compound 
concentration at a given point in time, and concentration biomarkers lack 
the time dimension, i.e. they are measured without any time units (Kaaks et 
al., 2002; Kaaks et al., 1997). In contrast to recovery biomarkers, the 
quantitative relationship between a concentration and intake, could differ 
between and within  individuals and populations depending on the presence 
and impact of determinants other than intake (Kaaks et al., 2002; Kaaks et 
al., 1997). Concentration biomarkers can be used as tools for ranking 
individuals according to dietary exposure rather than providing a reference 
method used to determine scaling factors for calibration of dietary 
questionnaires since a concentration biomarker can not be translated into an 
absolute estimate of intake (Kaaks et al., 2002; 1997). However, recent 
research has indicated that they may also play a role in calibration studies 
(Fraser et al., 2005; Fraser & Yan, 2007).  
 
Predictive biomarkers 
This category of biomarker was suggested by Tasveska et al. (2005). A 
predictive biomarker shows less absolute recovery than a recovery bio-
marker, but can be used for prediction of intake. The utility of this class of 
biomarkers for validation studies needs to be further investigated (Tasevska et 
al., 2005; 2008). Sucrose and fructose in 24-h urine samples were suggested 
to belong to this group (Tasevska et al., 2005).  
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1.3.5 Biomarker validity and reproducibility  
The  validity  of a biomarker can be defined as ‘the lack of systematic 
measurement error when comparing the actual observation with a standard, 
that is a reference method which represents the truth’ (Vineis & Gallo, 
2007). Kaaks et al. (1997) simply stated that the validity means that a ‘marker 
actually measures that it is intended to’ and also pointed out that most 
biomarkers cannot be translated into a measure of intake on an absolute 
scale, but only in most cases at the best provide a correlate to intake that can 
be used to roughly classify individuals according to high and low intakes. 
Maruvada & Srivastava (2004) defined the validity of an exposure biomarker 
as ‘the relationship between the biomarker and the actual exposure’. A 
biomarker might be valid at group level (providing a valid mean), but not 
necessarily at individual level (ranking individuals). This might be due to 
poor precision or different biases across subjects (Livingstone & Black, 
2003).  
 
The reproducibility of a biomarker describes the degree of correlation between 
samplings within the same individual on independent occasions (Kaaks et al., 
1997). Several authors use the terms reliability and reproducibility 
interchangeably (Al-Delaimy et al., 2008; Sonestedt et al., 2007; White, 
1997; Zeleniuch-Jacquotte et al., 1998), but Kaaks et al. suggested the term 
‘reliable’ to describe a biomarker that is both valid and has a high 
reproducibility. A low reproducibility might to some extent be compensated 
for by analysing several samples from the same individual and calculating an 
average, or by pooling samples taken on different occasions. A low validity, 
on the other hand (when random errors between replicate measurements are 
highly correlated), cannot be compensated for by using several measures 
(Kaaks et al., 1997). The reproducibility of a biomarker is largely determined 
by the stability of individuals’ intake of the food/nutrient of interest and the 
elimination half-life of the biomarker (Kaaks et al., 1997).  A short-half life 
might be compensated by a stable and continuous intake, as has been shown 
to be the case for vitamin C in plasma (Bingham et al., 1995).  
 
Reproducibility is commonly measured by the intra-class correlation coefficient 
(ICC), defined as: 
 
ICC = 
2 2
2
W B
B
 


,  
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where 
2
B   is the between-subject variation and 
2
W   the within-subject 
variation (Vineis, 1997). ICC values range between 0-1.0 and ICC is equal 
to 1.0 if there is exact agreement between repeated measures within the 
same individual (
2
W  = 0). This is different to a Pearson or Spearman 
correlation coefficient, which takes the value 1.0 when one measure is 
perfectly linearly related to the others, not necessarily when these agree 
exactly (Vineis, 1997). The ICC compares the impact of the between-
subject variability relative to the total variation and may therefore vary 
somewhat in different populations (Tworoger & Hankinson, 2006). A larger 
within-subject variation can be tolerated if the between-subject variation is 
also large (Vineis, 1997). The degree of reproducibility has implications for 
the power of a study and it should ideally be as high as possible (r 0.6-0.7)  
(Kaaks et al., 1997; Marshall, 2003). Day-to day reproducibility is likely to 
be higher than more long-term measurements (Kaaks et al., 1997; Marshall, 
2003). Estimated reproducibility can be used to correct for measurement 
error caused by ‘time-to time’ variation when comparing a single biomarker 
measurement with intake assessed by methods reflecting long-term intake, 
using the formula: 
 
 
k
r r observed true

   1  
 
 where  true r  is the corrected correlation coefficient,  observed r  is the observed 
correlation coefficient,   is the within- to between-individual variance ratio 
for the dietary measurement, and k is the number of replicated 
measurements per individual. This correction, called de-attenuation, can also 
be applied to situations where a single biomarker measurement is related to 
disease risk (Rosner & Willett, 1988; Willett, 1998). 
Validity and reproducibility are independent, meaning that a perfectly 
reproducible measurement might be consistently wrong, i.e. far from the 
‘truth’ (low validity) (Kaaks et al., 1997; Vineis & Gallo, 2007). In the 
converse situation, a biomarker might be unbiased, but measured with a low 
reproducibility, which will then give a broad and flat distribution around the 
true value (Vineis, 1997). A biomarker should ideally be both valid and 
reproducible, i.e. accurate, or what Kaaks et al. (1997) called reliable. 
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1.3.6 Desirable features of a dietary biomarker  
The usefulness of a dietary biomarker for use in epidemiological and for 
intervention studies is dependent on a number of factors affecting its 
reproducibility and validity. These factors might differ slightly between 
different biomarkers and few biomarkers have been fully characterised. 
Despite this, the use of biomarkers in epidemiology  should be encouraged, 
since it will assist in the elucidation of these aspects (Grandjean, 1995). Such 
general features are summarised below: 
Absorption 
The biomarker should ideally be absorbed to a consistent, preferably high, 
extent, with a low variation between and within individuals (Potischman, 
2003). However, a number of factors can affect absorption and hence distort 
the relationship between intake and biological measures (Potischman, 2003). 
Examples of such factors are differences in transit time and gastric emptying, 
food matrix and whether the biomarker is delivered as a bolus or on several 
occasions (Rowland & Tozer, 1995). 
Specificity 
Ideally, the biomarker should be specific to what it is intended to reflect 
(Marshall, 2003). However, factors other than intake which affect the 
biomarker is need to be identified and controlled for statistically (Kilkkinen 
et al., 2001; Vineis, 1997). These factors could be endogenous or exogenous 
and a comprehensive understanding of the fate of the biomarker in the 
human body, may be of help in identifying these factors (Maruvada & 
Srivastava, 2004; van Kappel et al., 2001). A biomarker might be sufficiently 
specific in one population but not in another (Peeters et al., 2007).   
Sensitivity 
The biomarker concentration needs to be sensitive to intake, meaning that 
even a small change in intake should be possible to detect. The sensitivity is  
in turn dependent on a number of factors, such as bioavailability and 
homeostatic regulation mechanisms (Hunter, 1998; Marshall, 2003; Spencer 
et al., 2008). 
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Temporal relationship with intake 
It is crucial to know the time-frame during which a biomarker reflects 
intake and to have an insight into its pharmacokinetics (Schulte & Talaska, 
1995; Verhagen et al., 2004). The elimination half-life needs to be known, 
since it will largely determine whether the biomarker is able to reflect daily, 
weekly, monthly or yearly intake (Marshall, 2003). A biomarker of 
exposure, which is related to disease endpoint, should ideally reflect the 
mean exposure over the etiologically relevant time period (White et al., 
1998). For chronic diseases such as cancer and CVD, this time period is long 
and thus biomarkers reflecting long-term exposure are highly warranted 
(Potischman, 2003). The degree of long-term reflection is not only 
dependent on the biomarker half-life but also on the regularity and stability 
of intake (Kaaks et al., 1997; van Dam & Hu, 2008). 
Stability 
In order to reflect intake of a certain food, the biomarker needs to be stable 
in the food and withstand processing/cooking in order to avoid 
confounding the food exposure estimate (Wild et al., 2001). Biological 
specimens used for biomarker assessment need to be appropriately handled 
in order to avoid introducing errors inherent to the stability of the marker. 
Caution is needed regarding choice of anticoagulant, preservatives, freezing-
thawing cycles and storage temperatures (Tworoger & Hankinson, 2006). 
1.3.7  Measurement error and its implications for biomarkers 
Measurement error is a measure of the deviation from trueness (Blanck et al., 
2003). For example, in the case of a concentration biomarker, the 
measurement error in the biomarker can be defined as the difference 
between an individual’s measured biomarker concentration and the true 
biomarker concentration, where the true biomarker concentration is the 
theoretical concentration given without any laboratory or other sources of 
error (White, 1997). If the biomarker concentration fluctuates, the ‘true’ 
concentration is the mean over the time period assessed (White, 1997). All 
methods of measurement include an error and this measurement error can 
be divided into 1) random errors or 2) systematic errors (bias) (Beaton, 
1994).  
 
An error is considered random if it is without any predictable direction. The 
random error may be a function of noise in estimation of true intake, errors 
in the analysis of food composition, or true day-to day-variation in food 
intake (Tarasuk & Brooker, 1997). The random error affects the precision in   27 
classifying subjects according to their habitual intake and a large random 
error, due to methodological or biological reasons, generally leads to 
attenuation bias, i.e. biases risk estimates toward null and lessens the 
likelihood of detecting a significant association between diet and disease 
(Tarasuk & Brooker, 1997; White et al., 1998).  
 
Biomarker measurement errors originate from a number of sources and can 
be divided into pre-analytical and analytical measurement errors (Blanck et 
al., 2003; Tworoger & Hankinson, 2006; White, 1997). Biomarker 
measurement errors can be differential or non-differential, which severely 
affects the usefulness of the biomarker in different study designs. In a case-
control study, for example, a differential error may arise if the biomarker 
concentration is affected by any process which is involved in the 
development of the disease and not only by exposure (White, 1997). 
 
Differential measurement error can bias disease risk estimates in both 
directions (White, 1997), whereas non-differential measurement errors only 
cause attenuated risk estimates, since non-differential misclassification is a 
function of precision of the biomarker measurement and not the bias. The 
lack of precision will lead to flattened distributions which will cause more 
overlap and hence less distinction between the distributions (biomarker 
measurements of the cases and controls) (White, 1997).  
 
Tools to estimate true dietary intake without any measurement error are 
limited. Hence, the ability to accurately estimate the measurement error in a 
calibration study and use it for correction of risk estimates is negatively 
affected (Thiebaut et al., 2007). A biomarker has the potential to provide an 
unbiased estimate of actual intake and to be without errors that correlate to 
those of the self-reported assessment method (Prentice et al., 2004). To 
better understand dietary measurement errors, new ‘recovery biomarkers’ 
and methods to combine ‘concentration biomarkers’ which do not fulfill the 
requirements for reference measurements but do correlate with intake with 
dietary assessment methods, are warranted (Prentice et al., 2002; 2004). A 
good biomarker should preferably have a measurement error variance that is 
rather small (< 50%) relative to the actual consumption (Prentice et al., 
2004).  
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1.3.8 Biomarker validation steps 
Both traditional dietary assessment instruments and biomarkers need to be 
validated (Andersen et al., 2005; Slotnick & Nriagu, 2004). There are 
different strategies to evaluate a dietary biomarker, which may involve 
controlled animal experiments, geographical studies where intake and 
biomarker correlations are studied in observed populations, and controlled 
experiments which allow time integration of dose-response relationships 
(van't Veer et al., 1993). When a biomarker has been independently 
validated and is known to reflect intake, the study design can be reversed, 
and dietary assessment methods can be validated against the biomarker 
(Hunter, 1998). If the biomarker is to be used for validation of the accuracy 
in other dietary assessment methods, studies under controlled conditions are 
needed to assess the predictability of the biomarker (Bingham, 2002). Only a 
few biomarkers of dietary intake have been evaluated in this way (Bingham, 
2002).  
 
Biomarker validation requires several steps (Figure 4), where sensitivity to 
intake, as well as determinants other than intake and temporal reflection of 
the biomarker need to be investigated (Hunter, 1998). The biomarker 
validation process is an iterative procedure resulting in a degree of validity, 
which may not be satisfactory until the biomarker is implemented (Slotnick 
& Nriagu, 2004).  
Exposure Biomarker value Health outcome
Sensitivity
Temporal relation
Bioavailability
Dietary and non-
dietary ’modifying’
factors
Specificity
Contamination
Levels in population
Sensitivity
Intra-/inter-
personal variability Stability
Disease status 
Genetic
polymorphisms
Figure 4. Different aspects affecting the exposure-biomarker-health outcome relationship and 
that need to be included in the biomarker validation process. Model modified  from Slotnick 
& Nriagu (2004). 
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New biomarkers should be evaluated in small, well-defined, controlled 
studies before larger population studies are addressed, and a combination of 
evaluation approaches may be needed in order to validate the usefulness of 
dietary biomarkers (Maruvada & Srivastava, 2004).   
 
The main aim in biomarker validation is to characterise biomarker variability 
and evaluate its ranking capacity (Kaaks et al., 1997; Vineis, 1997). The 
variability is due to biological differences (including within- and between-
subject variation), measurement error (including laboratory errors), and 
random error (unexplained variance) forming the total variability within the 
group, which is the weighed sum of the different components (inversely 
correlated to the number of subjects, number of measurements per subject, 
the analytical replicate, respectively) (Vineis & Perera, 2007). In order to 
enable appropriate adjustment for variability, Vineis & Perera (2007) 
suggested that each variance component needs to be accurately estimated by: 
 
1. Determining the variability in laboratory measurements used  
2. Collecting information on sampling conditions that might affect the 
results 
3. Taking repeated samples whenever possible to allow for determination of 
the short, medium and long-term variation in the biomarker within 
subjects 
4. Collecting relevant subject information that might explain inter-subject 
variation 
 
Evaluation of the ranking capacity of a biomarker as a measure of dietary 
intake has hitherto been conducted by simply correlating the biomarker 
with intake estimated by traditional dietary instruments. Validation derived 
from correlation to another dietary instrument is regarded as the ‘upper-limit 
of the validity’ since the biomarker is compared with an imperfect method 
and since some of the errors in the biomarker are correlated over time 
(Kaaks et al., 2002). In a ‘perfect’ validation study, the biomarker would be 
compared with a method with no measurement errors, but such a method 
does not exist (White, 1997). Kaaks (1997) has recommended the method of 
triads for validation studies when data from a questionnaire, a biomarker and 
a ‘reference method’ (usually food records) are available. This method can 
be used to estimate the validity coefficient of each method, i.e. the 
correlation between observed intake (or a biomarker measurement 
correlated to intake) and the true intake. The assumption is that each 
method is linearly correlated to the same true intake and that the errors of 
the different methods are independent (Kaaks, 1997). Because the latter   30 
assumption may not always hold and violation will lead to overestimation of 
validity coefficients, the estimated validity coefficients should be regarded as 
the ‘upper limit’ of the true validity coefficients. 
1.3.9 Using a biomarker as a surrogate for exposure 
Biomarkers can be used to measure exposure to certain foods or 
nutrients/non-nutrients in epidemiological studies either alone or as a 
complement to traditional dietary instruments. In the EPIC-Norfolk cohort, 
Vitamin C was used as a biomarker of fruits and vegetables and was inversely 
associated with IHD mortality (Bingham et al., 2008). The estimated 
protective effect was about the same as observed when using 7- day food 
diaries, whereas an FFQ failed to demonstrate any association (Bingham et 
al., 2008). Different phytoestrogens, mainly ENL, have been used as 
biomarkers of phytoestrogen intake and related to different cancer 
endpoints, since dietary assessment of phytoestrogen intake, especially 
lignans, has been hampered due to lack of database data and inconclusive 
results (Grace et al., 2004; Ward et al., 2008). In another EPIC study, plasma 
carotenoids, retinol and tocopherols were analysed as measures of exposure 
to these nutrients in relation to prostate cancer (Key et al., 2007). Overall, 
none of the nutrients was significantly associated with a risk of prostate 
cancer, although the reliability of the biomarker over a period of 1-2 years as 
well as up to 14 years was demonstrated to be high ICC = 0.6-0.8 and 0.3-
0.5, respectively (Comstock et al., 2001; van Kappel et al., 2001). 
1.3.10 Using a biomarker for validation and calibration studies 
Validation studies 
Validation of a dietary instrument is the evaluation of whether the 
instrument measurement truly reflects what it is supposed to measure, and 
the validity is affected by the strength of the association between the 
measurement and ‘true’ intake and the specificity, i.e. that the measurement 
only reflects the variable of interest (Kaaks & Ferrari, 2006; Ocke & Kaaks, 
1997). One way of validating dietary instruments is to use biomarkers, 
which may serve as reference for comparison of two (or more) other dietary 
methods (Bogers et al., 2003; van't Veer et al., 1993) in validation studies. 
The aim of a validation study is generally to estimate the validity coefficient, 
i.e. the correlation between questionnaire data and true habitual intake in 
subjects (Ocke & Kaaks, 1997). This is usually performed by comparing 
questionnaire measurements to multiple food records or 24-h recalls, 
corrected for attenuation caused by random errors in the reference methods   31 
(Ocke & Kaaks, 1997). The correlation coefficient is then taken as the main 
criterion to evaluate whether questionnaire measures habitual diet with 
sufficient accuracy (Kaaks et al., 1995; Walker & Blettner, 1985). The 
fundamental advantage of using a biomarker in validation studies is that the 
biomarker has errors that are very likely to be independent of those obtained 
by traditional dietary instruments (Willett & Lenart, 1998). Correlated errors 
between dietary assessment methods will lead to overestimation of the 
validity coefficients, whereas correlated errors within the dietary reference 
method will lead to underestimation (Ocke & Kaaks, 1997). Without 
additional information, it is impossible to predict which bias will 
predominate, under- or overestimation), and the validity determined is only 
‘relative’ (Ocke & Kaaks, 1997). 
Calibration studies 
Calibration, refers to determination of the relationship between two 
measurement scales (Kaaks et al., 2002). There is one scale for true dietary 
intake and another for measured dietary intake. Calibration in nutritional 
epidemiology means that values from one method are quantitatively related 
to values from a superior, standard method, i.e. calculating a calibration 
factor to be used to adjust relative risks derived from different questionnaires 
so that the estimated become unbiased (Kaaks et al., 2002). In contrast to a 
validation study, where the true between-subject variation is to be estimated 
as well as the variation among subjects by comparing a questionnaire to 
replicated dietary records or dietary record and biomarker, a calibration 
study uses a single measure of a ‘reference method’ such as weighed food 
record, 24-h dietary recall or a biomarker (Willett & Lenart, 1998). The 
procedure is to regress the more accurate method (which at a group level 
represents an unbiased estimate of true intake) on the questionnaire data 
(Willett & Lenart, 1998). A calibration study enables ‘rescaling’ of results 
obtained across different studies and study populations where different 
questionnaires have been used, and hence enables comparisons. Biomarkers 
can be used in calibration studies, and slopes of applied regression lines 
between biomarker measurement and questionnaire at group level can be 
compared between different populations where the same questionnaire has 
been used. The design of such a study has to be determined based on the 
between- and within- subject variation in the biomarker, the costs of 
laboratory analysis and the precision of laboratory measurements (Willett & 
Lenart, 1998).    32 
 
1.4 Alkylresorcinols as biomarkers of whole grain wheat and rye 
intake 
Alkylresorcinols (1,3-dihydroxy-alkylbenzene derivatives) are non-iso-
pernoid phenolic lipids present in several families of higher plants, algae, 
mosses, fungi and bacteria (Kozubek & Tyman, 1999). There is a large 
structural diversity, which is dependent on the source (Knödler et al., 2008; 
Kozubek & Tyman, 1999; Ross et al., 2004d).  
 
In wheat, rye and barley grains, AR form one of the major groups of 
phenolic compounds (Ross et al., 2004c). The most common AR comp-
ounds in cereal grains are the 5-n-alkyl-derivatives with odd alkyl chain-
length commonly in the range of 17-25 carbon atoms, but different 
derivatives including 5-alkenyl-, 5-oxoalky-, and 5-hydroxyalkylresorcinols 
are also present to a minor extent (Figure 5). The highest proportion of 
unsaturated derivatives is found in rye, which contains about 20% of AR 
compounds other than 5-n-alkyl-derivatives (mainly 5-alkenylresorcinol) 
(Knödler et al., 2008; Ross et al., 2004c). 
 
 
 
 
 
 
 
 
 
 
Figure 5. The major 5-n-alkylresorcinols found in cereal grains. The common homologues 
have odd alkyl chains in the range of C17:0-C25:0 (from top to the bottom). 
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1.4.1 Alkylresorcinol occurrence  
Alkylresorcinols in cereal grains 
Among plants commonly used for human consumption, AR are present in 
high amounts in rye (Secale cereale), common wheat (Triticum aestivum), 
einkorn wheat (Triticum monococcum), emmer wheat (Triticum dicoccon), spelt 
wheat (Triticum spelta) and durum wheat (Triticum durum) (Andersson et al., 
2008a; Chen et al., 2004; Kulawinek et al., 2008; Landberg et al., 2005; 
Nyström et al., 2008) and in lower amounts in barley (Hordeum vulgare) 
(Andersson et al., 2008b; Zarnowski et al., 2002) (Table 4). Small amounts 
(<5μg/g) have also been reported in maize (Zea mays) (Gembeh et al., 2001) 
and in garden peas (Pisum sativum) (not a cereal grain) (Kozubek & Tyman, 
1999). The content varies within and between species but the relative 
homologue distribution is rather constant within species (Table 4) (Chen et 
al., 2004; Ross et al., 2003b).  
Table 4. Alkylresorcinol content range and C17:0/C21:0 ratio reported in cereal grains commonly used 
for human consumption  
Cereal Range 
(μg/g DM) 
 
AR 
C17:0/C21:0 
ratio 
References 
Rye 
(Secale cereale) 
568-1231 0.80-1.30  (Chen  et al., 2004; Kulawinek et al., 
2008; Mattila et al., 2005; Nyström 
et al., 2008; Ross et al., 2001a) 
Common wheat 
(Triticum aestivum) 
300-943 0.09-0.24  (Andersson et al., 2008a; Chen et al., 
2004; Hengtrakul et al., 1990; 
Mattila et al., 2005) 
Durum wheat 
(Triticum durum) 
194-687 0.01-0-02  (Andersson et al., 2008a; Ross et al., 
2003b) 
Einkorn wheat 
(Triticum monococcum) 
545-654 0.04  (Andersson et al., 2008a; Ross et al., 
2003b) 
Emmer wheat 
(Triticum dicoccon) 
531-784 0.05  (Andersson et al., 2008a; Ross et al., 
2003b) 
Spelt wheat 
(Triticum spelta) 
490-741 0.09-0.14  (Andersson et al., 2008a; Ross et al., 
2003b) 
Barley  
(Hordeum vulgare) 
8-210 0.05-0.46  (Andersson et al., 2008b; Chen et al., 
2004; Zarnowski et al., 2002) 
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The AR C17:0/C21:0 ratio has been suggested as a tool to distinguish 
between different cereals  (Chen et al., 2004) since the ratio is  1.0 for rye, 
  0.1 for common wheat and  0.01 for durum wheat (Andersson et al., 
2008a; Chen et al., 2004; Landberg et al., 2005)  (Table 4). 
 
In the cereal kernel, AR are located in the outer parts of the kernel (Ross et 
al., 2001a; Ross et al., 2004c; Tluscik, 1978). It was recently shown that > 
99% of the AR content is present in the outer cuticle of testa/inner cuticle 
of pericarp in hand-dissected grain samples (Figure 6) (Landberg et al., 
2008b). 
 
 
Figure 6. Light microscopy of a transversal cryo-section of a rye grain kernel stained by Fast 
Blue B. Alkylresorcinols appear violet.  
Alkylresorcinols in cereal food products 
After milling, the bran fraction contains higher amounts of AR, than whole 
meal while no or very small amounts of AR can be detected in germ and 
refined flour (Table 5) (Kulawinek et al., 2008; Landberg et al., 2008b; 
Mattila et al., 2005; Ross et al., 2003b).  
 
 
 
 
 
Aleurone layer 
Testa 
Pericarp  Outer cuticule of testa /inner 
cuticule of pericarp  35 
Table 5. Alkylresorcinol content and AR C17:0/C21:0 ratio determined by different analytical 
methods in different technological cereal fractions and food samples   
Product Total  AR 
content
1 
(μg/g 
DM) 
AR 
C17:0/
C21:0
2 
Samples 
(n) 
Analytical 
method 
Reference 
Rye bran  2466-
4100 
0.9 8  Colorimetry, 
GC, HPLC 
(Chen et al., 2004; Kulawinek 
et al., 2008; Mattila et al., 
2005; Ross et al., 2003b) 
WG rye 
(meal) 
888-927 0.9  5  HPLC,  GC  (Chen et al., 2004; Kulawinek 
et al., 2008; Mattila et al., 
2005; Ross et al., 2003b) 
Refined rye  44-286  0.9  6  HPLC, GC  (Chen et al., 2004; Kulawinek 
et al., 2008) 
WG rye 
bread 
197-686 0.9-1.1  11  Colorimetry, 
HPLC, GC 
(Chen et al., 2004; Kulawinek 
et al., 2008; Mattila et al., 
2005) 
Crisp bread 
(rye) 
490-1007 0.9-1.1 16  GC  (Chen et al., 2004; Ross et al., 
2003b) 
Breakfast 
cereals (rye) 
721 -  1  HPLC  (Kulawinek et al., 2008) 
Wheat bran  2670-
3225 
0.1-0.3 3  GC,  HPLC  (Mattila et al., 2005; Ross et 
al., 2003b) 
WG wheat  269-339  0.08-
0.1 
3 Colorimetry, 
GC 
(Chen et al., 2004; Kulawinek 
et al., 2008) 
WG wheat 
bread 
140-497 0.1-0.2  11  Colorimetry, 
GC 
(Chen et al., 2004; Kulawinek 
et al., 2008; Ross et al.,2003b) 
Wheat crisp 
bread 
58 -  4  GC  (Chen et al., 2004; Ross et al., 
2003b) 
Breakfast 
cereals 
(wheat) 
131-1784 0.08-
0.27 
5 HPLC  (Chen et al., 2004; Kulawinek 
et al., 2008) 
WG pasta  215-270  0.01-
0.03 
5 GC  (Landberg et al., 2005) 
Wheat flour 
(refined) 
ND-44 -  3  GC,  HPLC (Mattila et al., 2005; Ross et 
al., 2003b) 
Refined 
wheat bread 
ND-23 -  8  Colorimetry, 
GC, HPLC 
(Chen et al., 2004; Kulawinek 
et al., 2008; Mattila et al., 
2005) 
Oat bran  ND  -  -  HPLC, GC  (Mattila et al., 2005; Ross et 
al., 2003b) 
1Total AR content is the sum of C17:0-C25:0 (as determined by GC), the sum of akyl- and 
alkenyl-derivatives of C17:0-C25:0 (as determined by HPLC) and the sum of all 1,3-
dihydroxy alkylbenzene derivatives present (as determined by colorimetry). 
2Determined by 
GC.   36 
There is a large variation in AR content among different food products, 
determined by the milling extraction rate and the natural variation in 
content in wheat and rye (Table 5). Earlier methods investigating AR 
content in cereal food products suggested that AR were partly degraded 
during processing due to the lower contents detected in foods compared 
with raw ingredients (Al-Ruqaie & Lorenz, 1992; Verdeal & Lorenz, 1976; 
Winata & Lorenz, 1997). However, it was later demonstrated that this is due 
to entrapment of AR in the sample matrix during hydrothermal processing, 
probably as starch-lipid complexes, rather than degradation (Ross et al., 
2003b). Chen et al. (2004) showed that AR homologues were extracted 
with quantitative yield by using hot-propanol:water (3:1, v/v) for the 
analysis of foods and the corresponding ingredients. Studies where solvent 
extraction at room temperature has been used are likely to underestimate 
AR content.   37 
1.4.2 Analysis of alkylresorcinols in cereals and foods 
A number of different analytical techniques for qualitative and quantitative 
analysis of AR in cereal grains and products have been presented over the 
years, as reviewed by Kozubek & Tyman (1999) and Ross et al. (2004d). 
Some commonly used quantitative techniques are presented in Table 6. It is 
important to bear in mind that results from different analytical methods may 
differ, and results obtained from older methods in particular need to be 
evaluated with some caution (Ross et al., 2004d). HPLC methods may 
overestimate AR C17:0/C21:0 ratio, since alkylresorcinol homologues may 
co-elute with the following alkenylresorcinol homologue, e.g. C17:0 co-
elutes with C19:1 (Heiniö et al., 2007; Mattila et al., 2005; Seitz, 1992).  
Table 6. Quantitative methods used for the analysis of alkylresorcinols in cereal grains and food 
products.  
Assay AR 
quantified 
Extraction Detection  Evaluated
1  Reference 
Fluorometry  Total AR   Acetone  Fluorescence 
( = 350, 470) 
No (Evans et al., 
1973; Verdeal & 
Lorenz, 1976; 
Wieringa, 1967) 
Colorimetry
2  Total AR   Acetone, 
ethanol, 
methanol 
Visible 
absorption ( = 
520 nm) after 
reaction with 
Fast Blue B 
Yes (Andersson et al., 
2008a; Gadja et 
al., 2008; 
Landberg et al., 
2008a; Tluscik et 
al., 1981) 
HPLC
  Total AR, 
individual 
AR 
homologues
3 
Methanol, 
ethanol, 
acetone 
UV/diode 
array- 
detection  
( = 520 nm) 
No (Francisco et al., 
2005; Mattila et 
al., 2005; Mullin 
et al., 1992) 
GC Total  AR, 
individual 
AR 
homologues
3 
Ethyl 
acetate, 
acetone 
Flame 
ionisation 
detector (FID) 
Yes (Gohil et al., 
1988; Landberg et 
al., 2008a; Mullin 
et al., 1992; Ross 
et al., 2001a) 
1Evaluation of method including at least the following steps: determination of limit of 
detection/quantification (LOD/LOQ), determination of within- and between day variability 
(precision of the method), testing applicability > 10 different samples. 
2 AR reacting with 
azo-compound to form an azo-complex which can be detected spectrophotometrically. 
3HPLC methods published have not shown complete separation between alkyl- and     
alkenylresorcinols.   38 
1.4.3 Alkylresorcinols absorption, distribution and elimination 
Absorption 
Absorption has been defined as the process by which unchanged drug or 
xenobiotic/bioactive compounds proceeds from the site of administeration 
to the site of measurement within the body (Rowland & Tozer, 1995). The 
site of measurement in humans is often the blood. Like compounds with 
similar lipophilicity, AR are absorbed in the upper GI-tract and in-
corporated into chylomicrons, which are distributed to the circulation via 
the lymphatic system (Linko-Parvinen et al., 2007; Ross et al., 2003c). 
Linko-Parvinen et al. (2007) showed that 70-80% of the total AR content in 
plasma occurred in total lipoprotein fractions and that no AR were found in 
the plasma water fraction, suggesting that AR, like tocopherols, are 
incorporated into chylomicrons and transported to the liver and thereafter 
incorporated into VLDL or HDL. The highest concentration of AR among 
the isolated lipoproteins was  found in HDL, which was suggested to be due 
to direct transfer of AR from chylomicrones and VLDL to HDL during 
lipolysis (Linko-Parvinen et al., 2007). AR, may be partly secreted directly 
from epithelial cells into portal venous circulation by HDL efflux, which has 
been demonstrated for tocopherols (Rigotti, 2007).  
 
Alkylresorcinol ileal digestibility has been estimated as a crude measurement 
of absorption in one study on pigs and one study on humans (Ross et al., 
2003a; Ross et al., 2003c). In the pig study, 20 pigs were fed four different 
diets; whole grain rye, fractions of pericarp-testa, enriched aleurone and 
starchy endosperm (Ross et al., 2003c). The daily AR intake was different 
for the different diets and ileal recovery varied according to the diet (which 
also represented different daily AR intake levels) and was on average 
37±7%, 21±7%, 40±5% for whole grain rye, pericarp-testa and enriched 
aleurone respectively. No AR were detected in pigs fed the starchy 
endosperm. It was suggested that 60-79% of the ingested AR dose was 
absorbed and that the amount absorbed was dependent on the matrix (or the 
dose). No clear difference in absorption for different AR homologues was 
observed (Ross et al., 2003c). In the human study, 10 ileostomy operated 
subjects were given a high fibre rye diet rich in AR (147 mg/d) and a low 
fibre wheat-based diet (no AR) in two meal frequencies (nibbling and 
ordinary). All subjects had both diets and both frequencies (cross-over 
design). The ileal recovery was about 60±7%, regardless of meal frequency, 
with no obvious difference between different homologues (Ross et al., 
2003c).     39 
 
Distribution 
Distribution has been referred to as reversible transfer to and from the site of 
measurement (usually the blood) (Rowland & Tozer, 1995). Due to the 
amphiphilic nature of the AR molecules they are easily incorporated into 
biological membranes (Kozubek, 1995; Kozubek & Demel, 1980; Kozubek 
& Demel, 1981; Ross et al., 2004b). Studies on rats and humans have shown 
that AR are distributed into erythrocyte membranes and into the adipose 
tissue of rats (Linko & Adlercreutz, 2005; Ross et al., 2004b). The levels in 
erythrocyte membranes are correlated to plasma concentrations in fasting 
blood samples and follow changes in intake in the same way as plasma 
concentration. Longer AR homologues are more readily incorporated into 
the membranes than shorter homologues (Linko & Adlercreutz, 2005). The 
kinetics and the nature of the transfer processes are still unknown. 
Metabolism 
Metabolism can be defined as the conversion of one chemical species to 
another (Rowland & Tozer, 1995). Metabolism is one way of facilitating the 
elimination of a xenobiotic compound, often by making it more polar in 
order to enable urinary excretion. Ross et al. (2003c) fed a single dose of [4-
14C]-labelled AR C21:0 to rats and found most of the radioactivity in faeces 
(61%) and in urine (31%). The radioactivity detected in urine was not due 
to free or conjugated AR, whereas 90% of the radioactivity in faeces was 
from the intact C21:0 (Ross et al., 2003c). the same research group later 
identified  two compounds in urine (3,5-dihydroxybenzoic acid  (DHBA) 
and 3-(3,5-dihydroxyphenyl)-propanoic acid (DHPPA)) as main AR 
metabolites (Ross et al., 2004c; 2004d; 2004e) and suggested a similar route 
of AR elimination as for tocopherols (Birringer et al., 2001). In this route, 
AR undergo cytochrome P450-dependent  -oxidation, followed by ß-
oxidation of the alkyl chain forming the two endproducts, DHBA and 
DHPPA (Figure 7). A certain proportion of the metabolites are found as 
glucuronide and sulphate conjugates in urine (Koskela et al., 2007).  Later 
studies have confirmed that the two main metabolites are derived from AR 
and a quantitative analytical method for their determination in urine and 
plasma  has been developed (Koskela et al., 2007).   40 
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Figure 7. Pathway of alkylresorcinol metabolism suggested by Ross et al. (2004c) exemplified 
by AR C17:0 degraded to 3-(3,5-dihydroxyphenyl)-propanoic acid (DHPPA) (lower left) 
and 3,5-dihydroxybenzoic acid (DHBA) (lower right). 
Excretion 
Excretion can be defined as the irreversible loss of an unchanged compound 
or its metabolite (Rowland & Tozer, 1995). The two major AR metabolites 
DHBA and DHPPA are transported via the blood to the kidney, where they 
are excreted in urine in free and conjugated forms (Koskela et al., 2007; 
2008; Ross et al., 2004e). In addition a small fraction of intact AR 
(predominantly C17:0) has been detected in urine after deconjugation (Ross 
et al., 2004e). In plasma, 10-30% of DHBA and 60-90% of DHPPA were 
found to be conjugated in a study on 64 Finnish women (Koskela et al., 
2008), whereas almost all AR metabolites were found unconjugated in urine 
when analysing the same sample with and without a deconjugation step 
(Koskela et al., 2007). The discrepancy might be due to a rather high 
variation between subjects and to the fact that samples from only 15 subjects 
were analysed in the study on urine. The amount of AR recovered as 
urinary metabolites after a single dose of AR in rats was about 33% after 
collection for 140 h (Ross et al., 2003c). However, no studies on recovery 
of AR metabolites in human urine collections have been reported, nor any 
study on the pharmacokinetics of AR metabolites.      41 
2 Aims of the thesis 
The overall objective of this thesis was to evaluate the features and 
applicability of AR as specific biomarkers of whole grain wheat and rye 
intake. This was achieved by the following specific aims: 
1) To develop a sensitive and repeatable GC-MS method for 
quantification of AR in small volume plasma samples. (I) 
2) To investigate the pharmacokinetics of AR in humans after a 
single dose. (II) 
3) To assess dose-response of plasma AR concentration and AR 
metabolite excretion in urine under controlled conditions. (III) 
4) To compare the estimated AR intake, derived from weighed food 
records, with plasma AR concentration in subjects participating in 
a whole grain intervention study. (IV) 
5) To determine the reproducibility of plasma AR concentration in 
subjects under controlled, constant intake conditions with low and 
high AR intake. (V) 
          
6) To investigate the variation in plasma AR concentration in samples 
from a free-living population and to find determinants of plasma 
AR concentration. (VI) 
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3 Materials and methods 
3.1 Reference compounds 
Alkylresorcinols, AR metabolites and internal standards used in the different 
studies are listed in Table 7.  
Table 7. Reference compounds used in the different studies
1. 
Trivial name  Supplier  Purity  Study 
Alkylresorcinols
      
C17:0  Reseachem Lifescience Burgdorf, 
Switzerland 
>95% by NMR 
and LC-MS 
I,III-VI 
C19:0  I,III-VI 
C21:0  I,III-VI 
C23:0  I,III-VI 
C25:0 
               
I,III-VI 
Metabolites      
DHBA
2  Sigma-Aldrich St. Louis, USA  >98 % by 
unknown method 
III 
DHPPA
3  Isosep, Tullinge, Sweden  >95% by NMR  III 
Internal standards
      
C20:0  Reseachem Lifescience Burgdorf, 
Switzerland 
>95% by NMR 
and LC-MS 
II-VI 
Methyl behenate 
(C22:0 fatty acid 
methyl ester) 
Larodan Fine Chemicals Malmö, Sweden  >99% by unknown 
method 
I-V 
1 Alkylresorcinol standards used in II were provided by Professor Kristiina Wähälä, University 
of Helsinki (>95 % purity, determined by unknown method). 
23,5-dihydroxybenzoic acid. 
33-(3,5-dihydroxyphenyl)-1-propanoic acid   44 
3.2 Instrumentation 
Instruments used for determination of AR in foods and plasma and AR 
metabolites in urine are summarised in Table 8. Details of temperature and 
solvent gradients etc. can be found in I-VI.  
Table 8. Instruments and columns used for determination of alkylresorcinols (AR) and their metabolites 
in the different studies. 
Instrument Analyte  Matrix  Column  Study 
Agilent 6890 GC
1 
(Agilent Technologies, 
USA)  
AR Foods  HP-5   
30m×0.25μm×0.25mm 
 
I-V 
GC 8000 coupled to a  
MD 1000 quadrupole 
mass spectrometer  
(Fisons Instruments, UK) 
AR Plasma  BP-1 
12m×0.25μm×0.22mm 
 
II 
Trace Ultra GC coupled 
to a Trace DSQ mass-
spectrometer 
(Thermo Fischer 
Scientific, USA) 
AR Plasma  HP-5   
30×0.25μm×0.25mm  
III, IV 
Trace Ultra GC coupled 
to a Trace DSQ II mass- 
spectrometer (Thermo 
Fischer Scientific, USA) 
AR Plasma  TR-5 
15×0.25μm×0.25mm  
V, VI 
HPLC-CEAD
2 
(ESA Biosciences, USA) 
AR 
metabolites 
Urine  Intersil ODS-3  
3×150mm 
III 
1GC, gas-chromatograph. 
2HPLC-CEAD, high performance liquid chromatography- 
coulometric electrode array detector.  45 
 
3.3 Quantitative analysis of alkylresorcinols and their 
metabolites 
Foods 
The analysis of AR in foods (II-III, and V) was performed after slight 
modification of the method described by Ross et al (2003b). In brief, 0.5 
milled sample mixed with internal standard (methyl behenate) was extracted 
by a mixture of hot 1-propanol:water (3:1, v/v) in a boiling water bath. 
Extracts were combined and an aliquot taken, which was dried and dissolved 
in ethyl acetate and injected into the GC without derivatisation. AR 
homologues were quantified using a relative response factor of 0.9 for all 
AR homologues compared with the internal standard. 
Plasma 
Two different analytical methods were used for the determination of AR in 
plasma (Table 9). Samples in II-III were analysed according to a method 
described by Linko et al. (2002) and samples in V-VI were analysed 
according to the method described in I, referred to as the method developed 
by Landberg et al. (I).  
Urine 
The two AR metabolites DHBA and DHPPA were analysed according to 
protocol A in the method described by Koskela et al. (2007) (III). In brief, 
urine was mixed with syringic acid (internal standard) and deconjugated 
overnight with -glucuronidase and sulphatase enzymes. An aliquot was 
mixed with methanol and HPLC mobile phase before injection into the 
HPLC-CEAD system.  
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Table 9. The two different methods used for analysis of AR plasma concentration (I-VI) 
Step Linko  et al. (2002)  Landberg et al. (I) 
Preparation  500 μL plasma + IS
1 (C20:0, 1.8μg/mL, 
20μL) + 500 μL de-ionised water 
50-200 μL plasma + IS (C20:0, 1.0 
μg/mL, 15 μL)  
 
Incubation  Overnight at 37°C  - 
Extraction  Sample is vortexed (2 min) with 3mL 
diethyl ether. The aqueous phase is 
frozen in a dry-ice-ethanol bath. 
Organic phase is poured off. Procedure is 
repeated 3 times and extracts are 
combined 
Sample is vortexed (2 min) with 4mL 
diethyl ether. The aqueous phase is 
frozen in a dry-ice-ethanol bath. 
Organic phase is poured off. Procedure is 
repeated 3 times and extracts are 
combined  
Preparation for 
purification 
Sample is evaporated to dryness under a 
nitrogen stream and dissolved in 300μL 
MeOH 
Sample is evaporated to dryness under a 
nitrogen stream and dissolved in 1 mL 
MeOH 
Sample 
Purification 
Sample is purified on DEAE-Sephadex 
A-25 gel in free base form according to 
Fotsis & Adlercreutz (1987) 
Sample is purified on a 3 cc/60 mg 
Oasis
® MAX SPE cartridges 
 
Gel preparation  See note 2  - 
Conditioning  -  1 mL 0.1 M NaOH in 70% MeOH 
 
Sample 
application 
Sample (in 300 μL MeOH) is loaded and 
tube rinsed with 300 μL MeOH 
1 mL sample (1.0 mL/min) 
 
Washing  Neutral lipids are eluted by 6 mL MeOH  Neutral lipids are eluted by 2 mL MeOH 
AR elution  AR are eluted with 6 mL 0.1 M acetic 
acid in MeOH 
AR are eluted with 3 mL 2% acetic acid 
in MeOH 
Derivatisation   Evaporation to dryness under a nitrogen-
stream. Silylation by 100 μL QSM
3 for 
30 min at room temperature 
Evaporation to dryness under a nitrogen-
stream. Silylation by 150 μL QSM for 30 
min at room temperature 
GC-MS 
analysis 
1 μL sample is injected into a GC-MS. 
AR homologues are quantified on their 
molecular ions or the base ion. 
Multipoint standard curves (n=6-8) are 
prepared for each homologue and for 
each batch 
1.5 μL sample is injected into a GC-MS. 
AR homologues are quantified on their 
molecular ions or the base ion. 
Multipoint standard curves (n=6-8) are 
prepared for each homologues and for 
each batch 
1IS, internal standard (C20:0). 
250 g DEAE-Cl
- is subsequently washed with 500 mL of 20%, 50% and 
100% EtOH. Ethanol is decanted and gel is resuspended in MeOH. Gel can be stored for 1 year at 8 °C. 
Before use, DEAE-Cl
- is converted to DEAE-OH
- by washing sequentially with 10 bed volumes of 0.1 
NaOH in 70% MeOH, 70% MeOH, 100% MeOH. Columns are manually prepared by adding gel into 
Pasteur pipettes to a final height of 1.5 cm. Sample needs to be applied immediately. 
3 QSM, quick 
silylation mixture (pyridine:HMDS:TMCS, 9:3:1, v/v/v)   47 
3.4 Quality assurance and method comparison 
Foods 
A milled whole grain rye sample was been included in every batch (n=2-3) 
throughout all studies. A batch was re-analyzed if the within-batch variation 
estimated as the coefficient of variation (CV) for total AR content exceeded 
10%, or if the mean for the control samples in the batch analysed exceeded ± 
2 SD of the mean determined for >10 batches. The within-day CV was 
usually <5% and between-day CV <10% for all individual AR homologues 
and for their sum. 
 
Plasma 
A control sample was included in every batch (n=3-5) along with a blank 
(water or silylation reagent). If the blank contained AR, the entire batch was 
re-analysed. In II, pooled plasma from the Finnish Red Cross study was 
used as the control sample (Linko et al., 2002), while in I, III-VI a fasting 
plasma sample from a person with high AR intake was used. The batch was 
re-analysed if the CV for total AR content in the control sample exceeded 
15% or if the mean of the control sample within a batch exceeded ± 2 SD of 
the mean of >8 determinations. The within-batch CV was <10% and the 
between-batch CV <11% for total AR determined when evaluating five 
replicate samples analysed in 20 batches (V and VI).  
 
The two methods for determination of AR in plasma used in the studies 
were compared by analysing 10 selected samples from II  and III to 
represent a wide sample concentration range (50-500 nmol/L). Samples 
were analysed in duplicates according to the procedures described in Table 
9, and mean values were used for investigation of method agreement.  
 
In addition, a small method comparison study was conducted, since samples 
in II were analysed at the Finnish laboratory and the rest at the laboratory in 
Uppsala. Plasma samples from II-IV were pooled in order to obtain three 
samples containing low, medium and high AR concentrations. Samples 
were blindly analysed in triplicate on one day (high and low concentration) 
and on three different days (medium concentration). The laboratory in 
Finland was unable to quantify the sample with low AR concentration at 
the time of the study, and hence this sample was omitted from the 
comparison.  
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3.5 Samples and study design 
Samples used for method development in I were taken from samples 
reported in III and pooled in order to obtain three levels corresponding to a 
low, medium and high AR concentration. Samples from VI were used to 
compare base and molecular ion quantification. Studies reported in II-V 
were controlled intervention studies, whereas samples in VI were taken 
from a case-cohort study. A summary of study designs and subject 
characteristics is presented in Table 10.   
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3.6 Assessment of pharmacokinetics 
Study II 
The absorption phase in six volunteers after a single dose of 190 mg AR was 
evaluated visually and by the method of residuals to determine whether 
absorption followed first-order kinetics (Rowland & Tozer, 1995). A one-
compartment model was used, since visual inspection of log-transformed 
plasma concentration curves showed no clear distribution phase. All 
pharmacokinetic parameters were calculated manually from plasma 
concentration data.  
Study III 
A population pharmacokinetic model was built by using non-linear mixed-
effect modelling on data from I (Ette & Williams, 2004a; 2004b). One- and 
two-compartment models were evaluated (II). In the final model, one 
central compartment was used to describe the distribution and absorption 
was assumed to occur from two different compartment, with different lag-
times, and the relative bioavailability from these two compartments was 
estimated. A baseline concentration was included in the model (since low 
AR concentration was detected despite no whole grain intake). The model 
developed was tested by comparing model-predicted plasma AR 
concentrations with those measured at recorded time points in III. The 
agreement between observed and predicted concentrations was investigated 
with a Bland-Altman plot (Bland & Altman, 1999). NONMEM VI with the 
first-order conditional estimation method was used for model building and 
simulation (Ette & Williams, 2004a; 2004b). Xpose 4 
(http://xpose.sourceforge.net) was used for model diagnostics.  
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3.7 Statistical analysis 
Comparison between laboratories and methods for AR analysis 
Differences between the two laboratories were tested using ANOVA with 
laboratory and day as fixed factors and sample as a random factor. 
Differences were considered significant at P<0.05. Minitab version 14.0 
(Minitab Inc, State College, PA, USA) was used for the statistical analysis. A 
Bland-Altman plot was used to compare agreement between the methods 
developed by Linko et al. (2002) and Landberg et al. (I) (Bland & Altman, 
1986; Bland & Altman, 1999). 
 
Study I-VI 
Statistical methods and approaches used in I-VI are summarized in Table 11. 
In all studies, normality was checked by the Shapiro-Wilk test and variables 
which departed from normality (P<0.05) were loge-transformed before 
statistical analysis. All correlation coefficients are Spearman´s rank correlation 
coefficients unless otherwise stated. P-values <0.05 were regarded as 
statistically significant, except for evaluation of potential carry-over effects 
(IV-V) where P<0.10 was used as the limit. In III and IV, P-values were 
Bonferroni corrected, in order to adjust for type 1 error.  In I-II Minitab 
14.0 (Minitab Inc, State College, USA) was used for all statistical analyis, 
whereas mainly SAS version 9.1 (SAS Institute Inc., Cary, N.C, USA) was 
used in study III-VI. 
 
 
 
 
 
 
 
   52 
 
Table 11. Statistical methods/procedures and models used in the different studies. 
Method/ 
procedure 
Response variable  Model
1  Study 
Factorial design   Total AR 
concentration              
Concentration level
2, water 
incubation, sample volume 
I 
ANOVA  Total AR conc.  Deproteination   
 AR  homologue 
recovery (%) 
Homologue, conc. level, 
homologue×conc. level 
 
ANOVA
3 PK-parameters
4 AR  homologue  II 
Linear regression    Relative homologue 
composition 
Time   
 
 
Relative 
bioavailability 
AR homologue   
Mixed linear model 
(Proc mixed)
5 
AR conc. 
C17:0/C21:0 ratio 
 
Period, dose, subject, [AR 
concentration before 
treatment]
1 
III 
  Metabolite excretion  Period, dose, subject   
  Metabolite recovery  AR intake, subject   
ANOVA
6 
(Proc GLM) 
Plasma AR,  
C17:0/C21:0 ratio 
Sequence, subject within- 
sequence, period, treatment 
IV 
ANCOVA 
(Proc GLM) 
Plasma AR 
 
AR intake, subject  IV 
ANOVA
6 
(Proc GLM) 
Plasma AR,  
C17:0/C21:0 ratio 
Sequence, subject within- 
sequence, period, treatment 
V 
Mixed linear model 
(Proc Mixed) 
Plasma AR (ICC)  Subject  V 
ANCOVA 
(Proc GLM) 
Plasma AR  Dietary
7, and non dietary
8 
factors 
VI 
1Random factors in italics and covariates are within brackets.
2Sample concentration levels 
tested were low, medium and high. 
3Tukey’s pair-wise comparison was used as post hoc test. 
4PK-parameters tested were  t1/2 and tmax. 
5 Bonferroni corrected t-tests were used as post hoc 
tests. 
6Carry-over effect was evaluated at the P< 0.10-level, by comparing treatment 
sequence, with subject nested within-sequence as the error term. 
7Dietary fibre, rye bread, 
white bread, crisp bread, other bread, beer, carcass animal fat, total energy intake.  
8Cholesterol (non-fasting), BMI, and time-since last meal  
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4 Results and discussion 
4.1 Analysis of AR in plasma ( (I)  
The original method for analysis of AR in plasma developed by Linko et al. 
(2002) was used in II-IV. In this method, a rather large sample volume (0.5 
mL) was used and samples were incubated over night with de-ionised water 
in order to release AR from proteins (Linko et al., 2002). Sample 
purification was performed using ion-exchange chromatography on columns 
manually prepared in the laboratory. For analysis of samples from 
epidemiological studies, a large number of samples usually need to be 
analysed and only small sample volumes are typically available.  Therefore, a 
new, faster method that required less sample volume was developed (I). A 
small method comparison study was undertaken to ensure comparability 
between the method of Linko et al. (2002) and that of Landberg et al. (I). 
 
Diethyl ether was the most suitable solvent for AR extraction, giving the 
highest recoveries and least co-extracted ballast substances when compared 
with pure chloroform and mixtures of chloroform and methanol (I). Linko 
et al. (2002) came to the same conclusion when comparing diethyl ether 
with petroleum ether, ethyl acetate, n-hexane and mixtures of n-
hexane:ethyl acetate (1:3 and 4:1 (v:v)), n-hexane:diethyl ether (1:1 and 1:3 
(v:v)) and diethyl ether:ethyl acetate (1:1 and 4:1 (v:v)) (Linko-Parvinen, 
2006). In contrast to what was found by Linko et al. (2002), water 
incubation did not affect the AR yield (P=0.72) or precision and was 
therefore omitted. Altering protein conformation by changing the pH did 
not affect AR yield or variation, nor did ethanol precipitation (P=0.10). 
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A significant interaction (P=0.04) was observed between sample volume and 
AR concentration, with somewhat higher concentrations when using 200 
μL plasma compared with using 500 μL was observed. However, the effect 
was small and probably not of practical importance.  For population- based 
non-fasting samples, a sample volume of 200 μL was found to be suitable. 
However, sample volume down to 50 μL can be used when the sample 
concentration is >80 nmol/L. 
 
The major development in the method was the use of a SPE column for 
sample clean-up. A mixed mode reversed phase, strong ion exchange 
sorbent was selected (Oasis® MAX) and different conditioning, sample 
application, washing and elution solvents and volumes were tested. AR 
homologue recoveries, estimated from spiking experiments using the 
procedure developed (Table 8) were 84-92% for the different homologues 
and 88±7 % for total AR (n=6) (I). No discrimination caused by the method 
(extraction and sample purification) of any AR homologue relative to C20:0 
(internal standard) was found when comparing slopes of standard curves 
prepared with and without sample matrix (P=0.09). This shows that analyte 
losses during sample extraction and purification are equal for different AR 
homologues and for the internal standard. 
 
The limit of detection (LOD) was in the range of 0.08-0.36 and the limit of 
quantification (LOQ) in the range 0.33-1.20 pg/injection for the different 
AR homologues. The lowest LOD and LOQ were found for C19:0 and 
C21:0. Overall, LOD and LOQ were up to ten times lower with the newly 
developed method (I) compared with the values found with the Linko et al. 
(2002) method. This might be due to less background noise obtained by the 
purification method used in the present method and/or to a higher 
sensitivity of the instrument used. Instrument sensitivity is also greatly 
affected by the number of samples analysed before cleaning the ion source.    
 
AR were quantified by GC-MS using the respective molecular ions m/z 
492 (C17:0), 520 (C19:0), 534 (C20:0), 547 (C23:0), 576 (C23:0) and 604 
(C25:0), with lower LOD and LOQ compared with when the base ion m/z 
268 was used. However, in some samples interference with unknown co-
eluting peaks might occur, and hence the base ion could be used for 
quantification as well. Both methods of quantifying AR showed satisfactory 
agreement for total AR concentration (I).  
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Method comparison studies 
The results by the Swedish and Finnish laboratories were comparable 
(Figure 8) and no statistical difference attributed to laboratory (P=0.16) was 
observed suggesting that results obtained in II-IV  are analytically comp-
arable.  
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Figure 8. Mean plasma total alkylresorcinol (AR) concentration (n=3) analysed on 
three different days at two different laboratories. Error bars represent standard 
deviation. Sample A= medium concentration, C = high concentration (analysed on 
day 1) 
 
There was also a satisfactory agreement between the method by Linko et al. 
(2002) and the method developed here (I) when the results of 10 samples 
analysed by both methods on the same occasion in the laboratory in Uppsala 
were compared (Figure 9). Method difference was independent of sample 
concentration (P=0.312). The difference between the methods was on 
average 10 nmol/L (on average higher values for the method by Linko et al. 
(2002)).  
 
 
   56 
 
-80
-60
-40
-20
0
20
40
60
80
0 100 200 300 400 500 600
Total AR concentration (method 1+ method 2)/2
T
o
t
a
l
 
A
R
 
c
o
n
c
e
n
t
r
a
t
r
a
t
i
o
n
 
b
y
 
m
e
t
h
o
d
 
1
 
-
 
m
e
t
h
o
d
 
2
 
  
 Figure 9. Bland-Altman plot showing the agreement between the methods by Landberg et al. 
(I) (method 1) and by Linko et al. (2002) (method 2). The bold line shows the average 
difference between the two methods and the dotted lines show the limits of agreement               
(-10±25 nmol/L) within which 95% of the observations are found 
4.2 AR pharmacokinetics (I II, III) 
Pharmacokinetics involve studies on the time-course of a drug/xenobiotic 
or a bioactive compound in the body, which is dependent on kinetic 
processes of absorption, distribution, metabolism and excretion (Rowland & 
Tozer, 1995). Primary parameters related to these processes determine the 
bioavailability and elimination half-life. No universally accepted term 
describing the corresponding events of nutrients and xenobiotics is available 
and terms such as ‘biokinetics’ or ‘kinetics’ have been used (Erlund, 2002). 
The term ‘biomarker kinetics’ has been suggested to be an analogous term to 
pharmacokinetics as regard biomarkers (Verhagen et al., 2004). In this thesis, 
the term pharmacokinetics is used to describe dynamic processes related to 
the absorption, distribution, metabolism and elimination (ADME) of AR. 
 
 
     +2SD 
     
    - 2SD   57 
One study on the pharmacokinetics of AR has been published previously, 
using plasma samples from pigs after a single dose and after a habitual diet 
rich in AR (Linko et al., 2006). A number of studies in both humans and 
animals have been conducted where absorption, distribution and elimination 
of AR have been studied without evaluating the pharmacokinetics (Linko-
Parvinen et al., 2007; Linko & Adlercreutz, 2005; Ross et al., 2003a; Ross et 
al., 2003c).  
 
Plasma AR concentration time profiles showed two absorption maxima in 
human subjects (tmax1=2.4-3.4 h and tmax2=6.4-5.5 h, for the different 
homologues) (Figure 10). This is in contrast to what was found for pigs, 
which showed only one absorption maximum after a single dose at tmax= 3-4 
h (Linko et al., 2006). The two absorption peaks in humans may be due to 
different physical absorption sites, effects of gastric emptying, second meal-
effects on digestibility, different pools or due to different absorption 
mechanisms (Charman et al., 1993; Deming & Erdman, 1999; Zhou, 2003). 
Enterohepatic circulation is unlikely to explain the two peaks, since the 
second peak is larger than the first. AR elimination half-life (t1/2) was 
estimated at 4.4-5.5 h for the different homologues with no statistically 
significant difference attributed to homologue, and was somewhat longer 
than that for pigs (Linko et al., 2006).  The longer elimination half-life 
observed for humans compared with pigs may be due to differences in body 
composition, hepatic blood flow, enzymes, etc. between pigs and humans 
(Lin, 1998).  
 
A pharmacokinetic model was fitted to the single dose-data (III) (Figures 10 
and 11). The best fitted model to explain the biphasic nature of the plasma 
concentration time profile had two absorption compartments with different 
bioavailability, lag-times and absorption rate constants (Figure 11).  
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Figure 10. Total AR concentration in plasma in six subjects after a single intake of rye bran 
flakes with the total AR content of 190 mg. The two Cmax and tmax indicated are mean values 
of all subjects   
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Figure 11. Pharmacokinetic model of alkylresorcinols. F1 = relative proportion of the dose 
absorbed from the first absorption compartment; F2 = relative proportion of the dose 
absorbed from the second compartment; lag-time1 = lag-time for start of absorption from first 
absorption compartment; lag-time2 = lag time for start of absorption from the second 
absorption-compartment; Ka1 = absorption rate constant from the first absorption 
compartment; Ka2 = absorption rate constant from second absorption compartment; Centeral 
= central compartment; baseline = baseline AR concentration (nmol/L); CL/V = 
clearance/volume of distribution   59 
The model developed was used to predict plasma AR concentrations in 
single samples taken at the end of intervention periods of III. The prediction 
error of the model (difference between simulated and observed value) was 
rather small in the light of the large variation between subjects that was 
observed in III and since single dose data from only six individuals were 
used to build the model (Figure 12).  
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Figure 12. Comparison between measured and predicted plasma total AR concentration 
(nmol/L) (III). The dotted line is the unity line. Model was built on data from II 
Even after a week-long wash-out period, which theoretically should be 
enough to clear AR from the systematic circulation, AR were still detectable 
at low levels (25- 68 nmol/L) (II-V). This has also been found in earlier 
studies on humans and pigs as well (Linko-Parvinen et al., 2007; Linko et al., 
2006; Linko et al., 2005; Linko & Adlercreutz, 2005; Linko et al., 2002).  In 
the PK-model, this AR concentration is referred to as ‘base-line’. It has been 
shown that AR are incorporated into erythrocyte membranes and into 
adipose tissue of rats (Linko & Adlercreutz, 2005; Ross et al., 2004b) and the 
‘base-line’ level probably reflects AR liberated mainly from the slow 
equilibrating adipose tissue pool. In addition, a low AR intake can be 
expected when consuming refined grain products, since some of those 
products have been shown to contain some AR (IV, VI).  The presence of 
AR in refined products is likely to be due to a high extraction rate in the 
milling process, since >99 % of AR are located in the bran fraction and no   60 
AR have been found in the starchy endosperm (Landberg et al., 2008b; 
Tluscik, 1978). 
Elimination 
The major fraction of the bioavailable AR is eliminated through hepatic 
metabolism and subsequent urinary excretion of free and conjugated DHBA 
and DHPPA, as suggested by Ross et al. (2004e). In the present study, the 
recovery of AR metabolites DHBA and DHPPA from ingested AR doses 
decreased with dose from  90% to about 45% (III). The reason for the 
difference in recovery is not clear, since results from different studies 
contradict each other. It may be due to a shift in AR elimination route at 
high doses or to 24-h being too short a time-period to completely recover 
high AR doses. A shift in elimination might be a consequence of biliary 
excretion of intact AR and/or metabolites at higher doses, a route which is 
known for -, -,and  -tocopherol and their carboxy-methyl-
hydroxychroman metabolites ( -, -,  and  -CEHC) (Kiyose et al., 2001; 
Swanson et al., 1999; Traber & Kayden, 1989). The lower recovery with 
increased dose might also be due to the presence of hitherto unidentified 
AR metabolites, most likely longer metabolites derived by fewer -
oxidation cycles. Such tocopherol metabolites have been found to be 
excreted in vivo (Birringer et al., 2001). Another explanation could be that 
AR absorption is dose-dependent and decreases with increased dose. Such 
an effect was observed in a pig study where Ross et al. (2003c) fed four 
different fractions of rye (whole grain, pericarp+testa, aleurone or starchy 
endosperm) containing different amounts of AR. However, such an 
explanation is counteracted by the rather linear increase (see Figure 15 
below) in plasma AR concentration observed across doses (III), which 
suggests that absorption is independent of dose. 
Bioavailability 
The relative bioavailability differed between AR homologues and increased 
with increased alkyl side-chain length (Figure 13). Homologue C25:0 was 
about five times as bioavailable as C17:0 and the relative homologue 
composition in plasma changed during the first 8 h after intake, with a 
significant decrease in C17:0 and a corresponding significant increase in 
homologues C23:0 and C25:0 (P<0.05) (Figure 14). Homologues C19:0 
and C21:0 did not change significantly during the corresponding time 
period (II).  
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Figure 13. Dependence of the number of odd carbon atoms in the AR side chain on 
normalized relative bioavailability (defined as AUCAR/doseAR × doseC17:0/AUCC17:0) 
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Figure 14. Relative plasma AR homologue composition after a single dose of rye bran flakes 
(corresponding to 190 mg total AR). Values are mean±SEM. Asterisks indicate a statistically 
significant trend (P<0.05) during 1-8 h   62 
Theoretically, the higher bioavailability of longer AR homologues as well as 
the relative increase in C23:0 and C25:0 and subsequent decrease in C17:0 
over time (Figure 14) may be due to higher absorption of longer AR 
homolgues. However, in a human ileostomy study, the tendency was the 
opposite, with small but significantly lower absorption for C23:0 and C25:0 
compared with the shorter homologues (Ross et al., 2001b). Another 
explanation for the difference in bioavailability might be a higher affinity of 
shorter AR homologues to the  -hydroxylease (enzymes involved in AR 
metabolism) in combination with a more extensive distribution of longer 
AR homologues into other compartments from where they are liberated 
back to plasma. Linko & Adlercreutz (2005) showed that longer AR 
homologues were more readily incorporated into erythrocyte membranes 
and we have found in an in vitro system that AR in RBC is transferred into 
plasma and equilibrium is reached within 3 days (unpublished data).  
4.3 Effect of intervention on AR plasma concentration (I III-VI) 
4.3.1 Plasma AR dose-response under controlled conditions 
Plasma AR concentration showed a rapid response to changes in AR intake 
in all studies, which can be expected due to the short half-life of 4-5 h and it 
increased significantly with increased intake in all studies (II-IV). The 
increase appeared to be linear with increased daily AR intake when given in 
the range 33-131 mg/d for all AR homologues (Figure 15, Table 12). This 
range well covers the consumption range found in the Nordic countries 
(Ross et al., 2004a).  
 
In two out of three intervention studies, AR were present at low 
concentrations ( 25 nmol/L) after periods when no foods known to contain 
them were allowed (during wash- out and run-in period) (Table 13). In 
addition, plasma from subjects with coeliac disease has been shown to 
contain no, or very low, AR concentrations (<7 nmol/L) (Linko-Parvinen, 
2006) and (I). The high AR concentration observed at wash-out in III can 
not easily be explained, but may be due to several reasons, including 
liberation of AR after a high habitual AR intake, samples taken early in the 
morning (short fasting period), and/or unintentional intake of products 
containing AR. Most subjects included in III were young, highly educated 
and with a healthy lifestyle, factors which are associated with high habitual 
whole grain intake (Harland & Garton, 2007).     63 
     
     
 
 
 Figure 15. Plasma alkylresorcinol (AR) homologues (C17:0-C25:0) and total concentration 
(nmol/L) after daily intake of 33, 66 and 132 mg of total AR by 15 subjects. At dose 0, an 
average from run-in and wash-out periods was calculated. Statistically significant differences 
were found between all doses for all homologues (P=0.001-0.034), except for homologues 
C21:0 and C23:0 between dose 1 and 2 (P=0.110 and P=0.097, respectively) (III).   
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Table 12. Estimated total alkylresorcinol (AR) intake and plasma total AR concentration in different 
intervention studies  
Study  AR intake  Plasma total AR 
concentration (nmol/L) 
Study 
 Advised 
(mg/d) 
Estimated 
(mg/d) 
  
Whole grain intervention 
(n=28)
1 
- 6.8±1.9
2 
65.0±12.2
3 
59±57 
202±107  
II 
Dose-response intervention 
(n=15)
1 
33 
66 
131 
- 
- 
- 
148±60 
210±81 
455±189 
III 
Rye whole grain/bran 
intervention 
(n=17)
1 
8.1 
620 
8.2±2.0
2 
556±160
4  
 
991±794 
75±92 
V 
1Subjects included in the statistical analysis. 
2Esimtated by 3 day weighed food records during 
refined grain treatment. 
3Estimated by 3 day weighed food records during whole grain 
treatment. 
4Estimated by 4 day weighed food records during rye whole grain/bran treatment 
Table 13. Plasma total AR concentration after washout periods in different studies 
Study  Wash-out period (d)  Plasma total AR 
concentration (nmol/L) 
Study 
RB/WB
1 intervention 
study (n=15)
2 
Run in 1w 
Wash-out 1w 
 23±7 (6-171) 
 25±3 (10-46) 
Linko-Parvinen 
et al. (2007) 
Kinetic study (n=6)
2  Run in 1w  25±9 (5-27)  II 
Dose response 
intervention, (n=15)
2 
Run in 1w 
Wash-out I, 1w 
Wash-out II, 1w 
68±33 (23-157) 
60±37 (35-178) 
65±33 (18-158) 
III 
1 RB, whole grain rye bread; WB, whole grain wheat bread. 
2 Subjects included in the 
statistical analysis 
 
The fasting plasma AR concentration after 6-8 weeks of habitual diet varied 
considerably reflecting differences in AR intake between subjects, different 
times since last AR-containing meal, different absorption and elimination 
capacities and analytical variation. The average habitual fasting total AR 
concentration was about 100 nmol/L in subjects participating in the 
intervention studies and both the magnitude of variation and the mean 
values were similar those found in comparable interventions in Finnish 
studies (Table 14). 
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Table 14. Habitual plasma total AR concentration reported from different studies. Values are reported 
as Mean±SD (range).  
Study  Plasma total AR
1 
concentration (nmol/L) 
Study 
Dose response intervention (n=15)
2 
(SWE) 
117±69 (46-253)  III 
Whole grain intervention (n=28)
2 
(SWE) 
102±70
3 (21-251) 
104±77
4 (23-340) 
IV 
Rye whole grain/bran intervention 
(n=17) 
(SWE) 
91±67
5 
140±73
6 
V 
Whole grain intervention, (n=39)
2 
(FIN) 
97±75 (34-418) 
88±54 (13-245) 
(Linko et al., 2005) 
Whole grain intervention (n=15)
2 
(FIN) 
127±212 (8-434) 
 
(Linko-Parvinen et al., 
2007) 
Case-cohort (n=362) (DAN)  115±112 (7-847)  VI 
1All samples were fasting samples except for those in VI. 
2Subjects included in the statistical 
analysis.
  3Values taken before whole grain intervention. 
4Values taken before refined grain 
intervention. 
5Values taken before whole grain/bran rye intervention. 
6Values taken before 
refined wheat intervention. A significant carry-over effect was detected (P<0.10) 
 
In IV, the relative validity of plasma AR concentration as a biomarker of 
whole grain of wheat and rye was evaluated by comparing plasma total AR 
concentration and estimated AR intake derived from 3-day weighed food 
records. The Spearman-Rank correlation coefficient was 0.58 when data 
from all study periods were combined. The increase in plasma AR 
determined by intake was highly significant (p<0.0001, as evaluated by 
ANCOVA model). In this study, no significant correlations were found 
during treatments, due to the small variation in intake between individuals 
resulting from the study design and good compliance. Correlation 
coefficients were 0.33 and 0.40 for periods with habitual diet period, before 
the respective treatment. The degree of correlation between estimated AR 
intake and plasma AR concentration was recently confirmed in a study on 
33 free-living Swiss subjects, where the correlation between AR intake 
estimated from 3-day weighed food records and plasma AR concentration 
was r= 0.57 (P<0.0001) (Dr. Alastair Ross, pers. Comm.. 2008).  
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When mean values, at group level, for the different treatments were 
compared across studies, a clear linear dose-response up to 131 mg AR/d 
was found (Figure 16). However, beyond this point, the shape of the plasma 
AR dose-response relationship is difficult to evaluate due to the large 
variation and since the only data used were from 17 men with extremely 
high AR intake (  550 mg/d) (V).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Plasma total AR concentration (mean±SD) after estimated or advised AR intake in 
different intervention studies. The insert also covers the high intake during the rye whole 
grain/bran intervention period of V 
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4.3.2 Plasma AR reproducibility at constant intake (V V) 
Reproducibility (largely determined by frequency of intake and the 
biomarker half-life) is a fundamental criterion of a biomarker, since it will 
affects the ability of a single sample to reflect intake over a certain time 
period (Kaaks et al., 1997; Sonestedt et al., 2007). In V, the reproducibility 
in plasma AR concentration was assessed in men with prostate cancer 
undertaking an intervention with constant high ( 550mg/d) or low ( 7.7 
mg/d) AR intake during two 6-wk periods. 
Table 15. Intra-correlation coefficient
1 (ICC) determined for the first and the second intervention period, 
(95% CI), n=17 
AR homologue  First intervention period  Second intervention period 
C17:0  0.94 (0.88-1.0)  0.89 (0.81-0.97) 
C19:0  0.89 (0.79-0.99)  0.90 (0.82-0.98) 
C21:0  0.86 ( 0.74-0.98)  0.80 (0.66-0.94) 
C23:0  0.89 (0.81-0.97)  0.85 (0.73-0.97) 
C25:0  0.92 (0.86-0.98)  0.88 (0.78-0.98) 
Total AR  0.90 (0.82-0.98)  0.88 (0.78-0.98) 
1Intra-class correlation coefficient defined as ( 
2
B)/ (( 
2
W) + ( 
2
B)), where  
2
B is the between-
subject variance and  
2
W is the within-subject variance. Variance components were estimated 
by a mixed linear model in SAS® v 9.1 (SAS Institute Cary, NC, USA) 
 
ICC was >0.85 with narrow 95% CI for all AR homologues. As a 
consequence of high ICC, 1-2 samples are needed in order to accurately 
assess individuals’ average plasma AR concentration during a 6-week period 
with constant AR intake (Table 16). A high ICC is due to either low 
within-subject variation and/or high between-subject variation (Vineis & 
Gallo, 2007). The within-subject variance expressed as the coefficient of 
variation (CV) was 11-18% and the between-subject variance was estimated 
to 27-69% depending on AR homologue and intervention period. The 
results show that plasma AR concentration is stable during conditions where 
the intake is regular (>3 times per day) and that 1-2 samples are sufficient to 
estimate the average AR concentration with an acceptable precision at a 
high confidence level (Table 16). It is likely; however, that plasma AR 
reproducibility is lower in a free-living population, where intake is more 
irregular.   
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Table 16. Estimated number of replicate samples needed from an individual to reflect the mean plasma 
total AR steady-state concentration corresponding to a certain intake during a 6-wk intervention period
1 
D
2-level
  First intervention period  Second intervention period 
 CI
3 (%) 
 80  95  80  95 
5  8 (7.7;8.3)  19 (18.7;19.3)  5 (4.7;5.3)  12 (11.7;12.3) 
10  2 (1.5;2.5)  5 (4.5;5.5)  2 (1.6;2.4)  3 (2.5;3.5) 
20  1 (0.3;1.7)  2 (1.2;2.8)  1 (0.4;1.6)  1 (0.08;1.9) 
30  1 (0.3;1.7)  1 (-0.1;2.2)  1 (0.4;1.6)  1 (0.08;1.9) 
40  1 (0.3;1.7)  1 (-0.1;2.2)  1 (0.4;1.6)  1 (0.08;1.9) 
50  1 (0.3;1.7)  1 (-0.1;2.2)  1 (0.4;1.6)  1 (0.08;1.9) 
75  1 (0.3;1.7)  1 (-0.1;2.2)  1 (0.4;1.6)  1 (0.08;1.9) 
90  1 (0.3;1.7)  1 (-0.1;2.2)  1 (0.4;1.6)  1 (0.08;1.9) 
1 Values are reported as point estimates (n=17) with the respective confidence intervals in    
brackets.
2Precision (%) with which a subject’s mean plasma total AR steady state level is to be 
estimated. 
3Confidence interval for the estimated number of samples needed to reflect the 
basal AR level with precision D 
4.4 Plasma AR concentration in free-living subjects (V VI) 
In  VI, potential plasma AR determinants were investigated by analysing 
samples and FFQs from 360 post-postmenopausal Danish women from the 
prospective ‘Danish Diet, Cancer and Health Study’. The frequency 
distribution of total AR concentration in non-fasting plasma sample was 
right skewed with a large variation (Figure 17). The shape of the 
distribution, with lower values being the most abundant, is similar to 
distributions of other biomarkers such as phytoestrogens in plasma and 
serum, plasma carotenoids and vitamin C (Grace et al., 2004; Jansen et al., 
2004; Kilkkinen et al., 2001; Kompauer et al., 2006; Nierenberg et al., 1991; 
Peeters et al., 2007). The mean plasma AR concentration was 115±112 and 
the range was 7-847 nmol/L (VI). These levels are approximately twice the 
fasting total AR concentration estimated for 57 free-living Finnish subjects 
(65±35 nmol/L). The variation is most likely caused by differences in fasting 
status, since cereal fibre intake was almost exactly the same in the two 
studies ( 10g/d) and since rye bread is the main source of cereal fibre for 
both Danes and Finns.    
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Figure 17. Frequency distribution of plasma total AR concentration in free-living Danish 
women (n= 360) (VI) 
Habitual total AR concentration in fasting plasma samples was higher in 
subjects from the intervention studies than in free-living subjects, where the 
concentration was 65.5±35 nmol/L (VI). The difference is most likely due 
to over-all higher consumption of whole grain/bran among subjects 
volunteering for the intervention studies. 
 
In  VI, both endometrial cancer cases (n=182) and randomly selected 
controls (n=178) were used since there was no difference between cases and 
controls regarding AR plasma levels. Both dietary factors (identified in the 
FFQ), likely to contain AR and non-dietary factors (such as BMI, time since 
last meal and total serum cholesterol) were investigated. Plasma AR 
concentration from a single sample was significantly correlated to rye bread 
intake (Spearman’s r=0.25 P<0.0001). The ‘true’ correlation coefficient is 
probably higher, since substantial attenuation is expected for the observed 
relationship to intake due to using non-fasting plasma sample and a single 
plasma sample (Rosner & Willett, 1988; White, 1997). When investigated 
by regression models, rye bread intake was identified as the only significant 
food determinant of plasma AR concentration and an increase in rye bread 
intake of 100 g/d was associated with an increase in plasma total AR 
concentration of 87 % (46-139, 95% CI) in the final model, where only 
foods likely to contain AR were included as factors (Table 17).    70 
Table 17. Estimated increment (%) in plasma total AR concentration corresponding to a 100 g/d 
increase in intake of food items, 10 g/d increase in fibre component and 1 unit increase in non-dietary 
variables. Potential determinants were identified among food items, fibre components and additional 
dietary factors evaluated by full and final models. Only estimates for significant (P<0.05) determinants 
are reported 
Possible determinants evaluated  Full model
1 Final  model
2 
Food items    
Rye bread  94 (-0.1; 153)  87 (46;139) 
Crisp bread  NS
3  NS 
White bread  NS  NS 
Other bread  NS  NS 
R
2 0.120  0.120 
    
Fibre components    
Total dietary fibre  22 (1; 49)  14 (0.3; 30)
4 
Cereal fibre  65 (19; 128)  37 (9; 74) 
Non-cereal fibre  NS  NS 
R
2  0.023 0.019 
    
Additional dietary factors tested    
Beer intake  NS  NS 
Fat derived from animal 
carcasses 
NS NS 
R
2 -  - 
1Model included all dietary factors and adjustment for BMI, serum cholesterol (non-fasting), 
total energy intake, time since last meal. 
2 Model included all dietary factors but excluded 
non-dietary factors. 
3NS, not statistically significant (P>0.05).
4 Univariate estimate. 
 
As expected, rye bread was the main determinant of the plasma AR 
concentration, since it is one of the richest sources of AR and since it 
accounts for 51% of total bread intake in the present study and about 65% of 
the total cereal intake in the Danish population (National Food Institute, 
2008). At a nutrient level, both total dietary fibre and cereal fibre intake 
were significantly associated with an increase of plasma AR concentration 
22% (1-49, 95% CI) and 65% (19-128, 95% CI) respectively. AR were not 
associated with other dietary fibre sources. The results are in agreement with 
findings by Aubertin-Leheudre et al. (2008), who recently showed plasma 
AR to be correlated to cereal fibre intake in free-living Finnish subjects 
(Pearson r= 0.28-0.42 for the different AR homologues, P<0.05).  
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About 12% of the total variation in plasma AR concentration was explained 
by the model for food items and about 2% for fibre components. The 
amount of explained variation is rather low and is likely to be due to 
measurement error in both the FFQ and in the biomarker. Errors in FFQ 
are likely to be due to a limited number of questions related to whole grain 
intake and due to a large variation in whole grain content in different 
products whereas errors in plasma AR concentration are likely to be due to 
using non-fasting samples and due to the fact that the biomarker is likely to 
reflect short-term intake, whereas the FFQ reflects more long-term intake. 
4.5 Plasma AR C17:0/C21:0 ratio- What does it show? 
The relative AR homologue profiles are rather stable within and between 
different cereal species, which results in C17:0/C21:0 ratios of about 1.0 for 
rye, 0.1 for wheat and 0.01 for durum wheat (Andersson et al., 2008a; 
2008b; Chen et al., 2004; Landberg et al., 2005; Ross et al., 2003b). It has 
been suggested that the plasma C17:0/C21:0 can be used to reflect the 
source of whole grain intake (Linko-Parvinen, 2006). Results from II 
showed that the relative abundance of C17:0 decreased in plasma over time 
whereas a corresponding increase was observed for C23:0 and C25:0. Hence 
the C17:0/C25:0 ratio decreased from about 0.8 to about 0.4 during the 
first 8 h after intake, and then remained stable until 24 h. These results 
suggest that there are differences in AR pharmacokinetics attributable to 
homologue length. However, the ratio was stabilised after 8 hours, but 
lower than that found in rye grain.  
 
Results from intervention studies, show that plasma AR C17:0/C21:0 ratio 
is changed according to intake of cereals from different sources, but that the 
ratio generally is lower than that found in the diet for rye intake and higher 
or equal to that found in wheat in the intervention studies (Table 18). This 
is probably explained by the lower bioavailability of C17:0 compared with 
C21:0 and by the fact that at low AR intake, a very small intake of rye will 
largely influence C17:0/C21:0 ratio.  
 
In free-living Danish women sampled in the period 1995-1997, the plasma 
AR C17:0/C21:0 ratios indicated mixed consumption of wheat and rye 
products (VI). The ratio was even higher among free-living Finnish subjects, 
and was in the same magnitude as observed for whole grain intake 
dominated by rye during intervention (Table 18). Both Finnish and Danish 
people consume large amounts of rye products (which are often whole   72 
grain). In Finland the rye bread intake is about 70 g/d (2007) and in 
Denmark it is somewhat lower, 58-65 g/d depending on year of survey 
(1995-2004) (National Food Institute, 2008; National Public Health 
Institute, 2007). The observed difference in plasma AR C17:0/C21:0 ratio 
is therefore likely to reflect differences in rye intake between the countries 
(Table 18). 
 
Table 18. The AR C17:0/C21:0 intake and plasma ratios in different intervention studies. Values 
are mean±SD 
 Dietary  AR 
C17:0/C21:0 
ratio 
Plasma AR 
C17:0/C21:0 
ratio 
Reference 
Intervention treatments     
Whole grain (6w, n=28)  0.36
1  0.30±0.23  II 
Refined grain (6w, n=28)  0.33
2 0.34±0.23  II 
Low dose of rye bran (1w, n=15)  0.80  0.35±0.15  III 
Medium dose of rye bran (1w, n=15)  0.80  0.45±0.31  III 
High dose of rye bran (1w, n=15)  0.80  0.64±0.52  III 
Rye whole grain/bran (6w, n=17)  1.06
3  0.65±0.24  V 
Refined wheat (6w, n=17)  0.15
3 0.27±0.22  V 
High fibre rye bread (8w, n=39)  ?  0.84±0.25  Linko et al. (2005) 
Low fibre wheat bread (8w, n=39)  ?  0.53±0.50   
Whole grain rye (1w, n=15)  1.02  0.60±0.23  Linko-Parvinen et 
al. (2007) 
Whole grain wheat (1w, n=15)  0.12  0.10±0.38  Linko-Parvinen et 
al. (2007) 
Free-living subjects     
Uncontrolled Danish diet, (n=360)  ?  0.40±0.23  VI 
Uncontrolled Finnish diet, (n=65)  ?  0.62±0.22  Aubertin-
Leheudre et al. 
(2008) 
1Ratio for advised whole grain diet for 6-week whole grain treatment. 
2 Ratio for advised 
refined grain diet for 6-week refined grain treatment. 
3Intake ratio was estimated from 4-day 
weighed food records 
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5 General discussion 
The validation of a new biomarker has been described as a long, costly and 
iterative process, where a range of expertise is needed (Bingham, 2002; 
Hunter, 1998; Maruvada & Srivastava, 2004; Schulte & Talaska, 1995). The 
validation of AR as biomarkers of whole grain wheat and rye may be 
summarised as in Figure 18. Each level of the model is discussed below. 
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Figure 16. A top-down model with five levels for the evaluation of AR as biomarkers of 
whole grain wheat and rye intake. This thesis mainly covered levels 2,3 and 4 in the 
validation model described   74 
 
Level 1  
AR have been shown to be specific for whole grain/bran of wheat and rye  
among commonly consumed foods and are found only at very low contents 
in refined cereal products (Chen et al., 2004; Landberg et al., 2008b; Mattila 
et al., 2005; Ross et al., 2003b; Ross et al., 2001a). AR in foods are stable 
throughout food processing (Chen et al., 2004). To facilitate evaluation of 
AR as biomarkers, food composition data need to be collected for the most 
commonly consumed whole grain/bran foods. Several analytical techniques 
are available for determination of AR content in food products (listed in 
Table 6), but systematic method validation is often lacking. 
Level 2 
A rapid and sensitive method for the analysis of AR in rather small plasma 
volumes (50-200 μL) is available (I). AR share similar absorption and 
elimination routes as tocopherols, as evidenced by the two major metabolites 
DHBA and DHPPA (Ross et al., 2004e). In the blood, AR are associated 
with lipoprotein fractions and also distributed to the membranes of 
erythrocytes (Linko-Parvinen et al., 2007; Linko & Adlercreutz, 2005). 
However, the magnitude of distribution and the mechanisms are unknown. 
In this thesis, recovery (of ingested dose) of AR metabolites in 24 h-urine 
was shown to decrease with increased dose (III). The reason for this needs 
to be studied before AR metabolites can be classified and used as biomarkers 
of whole grain wheat and rye intake. 
Level 3 
Plasma AR have a short elimination half-life (4-5 h) and can be classified as a 
short-term concentration biomarker (II-III). How well plasma AR 
concentration can reflect more long-term intake in free-living individuals is 
unknown and needs to be evaluated in different populations. AR liberated 
from slowly equilibrating body pools may reflect more long- term intake.  
Level 4 
Under intervention conditions, a rather strong correlation was found 
between plasma AR concentration and estimated intake (IV) and a high 
reproducibility at regular intake was observed (V). The validity and 
reproducibility of AR as a biomarker in free-living individuals is unknown. 
In VI, factors potentially affecting AR concentration were identified and 
tested. Among these factors, rye bread was the major determinant, although 
a rather small proportion of the total variance was explained.     75 
Level 5 
No endpoint study has so far been reported in the literature, nor any study 
where AR have been used to validate other dietary instruments.    76 
6 Main findings 
	 A rapid GC-MS method for determination of AR in relatively small 
plasma sample volumes (50-200 μL) was developed and evaluated (I). 
 
	 AR showed two plasma concentration peaks after a single dose and the 
highest concentration occurred after about 7 hours and was >2000 
nmol/L in all subjects (II). The apparent elimination half-life was   4.5h 
and hence, plasma AR concentration can be defined as a short-term 
concentration biomarker. A one-compartment pharmacokinetic model 
with two absorption compartments adequately described the single-dose 
AR pharmacokinetics (III) 
 
	 Fasting plasma AR concentration increased linearly with increased 
intake in human subjects with controlled intake of 33-131 mg total AR 
per day, which covers the whole grain intake range likely to be found 
among most people in Sweden (III). The relative validity of plasma AR 
concentration compared with intake estimated by 3-day weighed food 
records was high (r=0.58) when the intake range was broad (IV). 
 
	 The fasting plasma AR concentration reproducibility was high (ICC> 
0.85) during a 6-week intervention with constant intake. Generally, one 
fasting plasma sample can be used to assess subjects’ average 
concentration over a 6-week period with high accuracy and statistical 
precision (V). Hence, AR can be used to assess compliance in whole 
grain wheat and rye intervention studies. 
 
	 Non-fasting plasma AR concentration was mainly explained by rye 
bread intake among tested factors identified from a FFQ in free-living 
Danish subjects (VI).   77 
7 Future research 
 
	 A large number of samples from free-living subjects must be analysed if 
AR are to be used as a surrogate of whole grain intake wheat and rye in 
epidemiological endpoint or validation studies. Hence, a faster and 
cheaper method requiring less sample material for determination of AR 
in plasma samples needs to be developed and validated. 
 
	 It remains to be determined whether a specific AR homologue (or the 
sum) should be used as the biomarker.  
 
	 In this thesis, the main focus was to evaluate plasma AR as biomarkers. 
However, other biological samples can also be used and should be 
evaluated for more long-term reflection.  
 
	 Long-term reproducibility in free-living subjects from different 
populations needs to be estimated. Ideally, the reproducibility should be 
determined in a sub-group of the same population where endpoint-
studies are conducted, because this would allow correction for 
attenuation bias. 
 
	 A validation study where plasma AR is evaluated against other dietary 
assessment methods in free-living subjects is warranted to assess its 
validity coefficient (correlation to true intake). 
 
	 Since many prospective cohort studies use non-fasting samples, the 
feasibility of using non-fasting samples compared with fasting samples 
needs to be evaluated.   
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